Interim report
Page 1
GSK delivers strong Q3 performance and continued momentum Strong Specialty Medicines performance drives sales and core operating profit growth • Total Q3 sales £8.9 billion +4% AER; +5% CER • Specialty Medicines sales £3.9 billion (+15%); HIV sales £2.1 billion (+10%), Respiratory, Immunology & Inflammation £1.1 billion (+21%); Oncology £0.6 billion (+23%) • Vaccines sales £2.6 billion (-2%); Shingrix £0.8 billion (-5%); Meningitis vaccines £0.6 billion (+12%); and Arexvy £0.2 billion (-24%) • General Medicines sales £2.4 billion (stable); Trelegy £0.8 billion (+8%) • Total operating profit -16% and Total EPS -21% driven by Major restructuring charges of £328 million related to the Accelerate Growth programme and lower other net operating income, partly offset by Core operating profit growth • Core operating profit +5% and Core EPS +1% reflecting higher sales, favourable product and regional mix and higher royalty income, partly offset by increased investment in R&D and new asset launches and higher finance costs • Cash generated from operations of £3.1 billion with free cash flow of £2.1 billion (Financial Performance – Q3 2026 results unless otherwise stated, growth % and commentary at CER as defined on page 43. The quarter and year to dateadverse currency impact on AER versus CER primarily reflected the strengthening of Sterling against the USD. See page 8 for further details.) Q3 2026 Year to date £m % AER % CER £m % AER % CER Turnover 8,887 4 5 24,925 4 5 Total operating profit 2,127 (18) (16) 4,901 (28) (25) Total operating margin % 23.9% (6.4ppts) (6.1ppts) 19.7% (8.7ppts) (8.2ppts) Total EPS 38.5p (23) (21) 92.5p (26) (23) Core operating profit 3,076 3 5 8,526 5 7 Core operating margin % 34.6% (0.3ppts) (0.1ppts) 34.2% 0.3ppts 0.7ppts Core EPS 54.6p (1) 1 151.6p 4 6 Cash generated from operations 3,122 24 7,378 18 Continued pipeline progress: • Hibsago approved in US and Japan, with data showing unprecedented functional cure rates and potential to redefine treatment of chronic hepatitis B • Jemperli approved in US as first immunotherapy for adults with dMMR/MSI-H locally advanced rectal cancer • Positive registrational data for Jideytro in first-line ROS1-positive non-small cell lung cancer (approved in US in second-line in July) • Promising first global data for Ris-Rez in lung cancer; and positive phase I data for Mo-Rez in ovarian cancer • Shingrix pre-filled syringe approved in Japan, simplifying administration • mRNA seasonal influenza (flu) vaccine phase III trial initiated, following positive phase II data • On track to start 22 phase III trials in 2026 with 18 starts to date Growth outlooks: • 2026 guidance reaffirmed with expected growth in: turnover 3% to 5%; Core OP 7% to 9%; Core EPS 7% to 9% • On track for 2031 sales outlook of more than £40 billion • Operating margin stable to improving through dolutegravir loss of exclusivity period of 2028-2030 Shareholder returns: • Q3 2026 dividend of 17p declared; 70p expected for full year 2026 Luke Miels, Chief Executive Officer, GSK: “GSK has delivered another strong quarter, with our key growth drivers and new launches performing well. We remain focused on operational delivery, execution and accelerating R&D. Over recent months we have received 3 new specialty medicine approvals in the US: Hibsago, which has the potential to transform the treatment of chronic hepatitis B; Jideytro in non-small cell lung cancer; and Jemperli in rectal cancer. More broadly, in the late-stage portfolio, we are on track to start 22 phase III trials this year.” Guidance all at CER. The Total results are presented in summary above and on page 7 and Core results reconciliations are presented on pages 16 and 18. Coreresults are a non-IFRS measure that may be considered in addition to, but not as a substitute for, or superior to, information presented in accordance with IFRS.The following terms are defined on pages 43-44: Core results, AER% growth, CER% growth and other non-IFRS measures. GSK provides guidance on a Coreresults basis only for the reasons set out on page 14. All expectations, guidance and outlooks regarding future performance and dividend payments should be readtogether with ‘Guidance and outlooks, assumptions and cautionary statements’ on pages 45-46. Abbreviations are defined on page 49.
Page 2
2026 Guidance GSK reaffirms its full-year 2026 guidance at constant exchange rates (CER). Turnover is expected to increase between 3% to 5%, at the upper half of the range Core operating profit is expected to increase between 7% to 9%, at the upper half of the range Core earnings per share is expected to increase between 7% to 9%, at the lower half of the range This guidance is supported by the following turnover expectations for full-year 2026 at CER. Specialty Medicines – expected increase at a low double-digit percentage Vaccines – expected to be broadly stable to an increase at a low single-digit percentage General Medicines – expected decline of a mid-single digit to low single-digit percentage Core operating profit is expected to grow at the upper half of the 7 to 9 per cent range at CER. GSK continues to expect to deliver gross margin accretion due to improved product mix from Specialty Medicines growth and continued operational efficiencies. In addition, GSK anticipates further leverage in Operating profit as we accelerate ongoing productivity initiatives and take a returns-based approach to SG&A investments, with SG&A expected to be broadly stable year-on-year. R&D is expected to grow significantly ahead of sales as we accelerate investments in the pipeline as part of the Accelerate Growth programme while driving operational efficiencies. Royalty income is expected to be around £900 million. Core earnings per share is expected to increase at the lower half of the 7 to 9 per cent range at CER, reflecting higher interest charges of around £700-750 million, including the impact of the Nuvalent acquisition, and the tax rate which is expected to rise to around 17.5%, offset by the expected benefit from the share buyback programme. Expectations for non-controlling interests remain unchanged relative to 2025. Agreement with US Government to lower the cost of prescription medicines for American patients As previously announced, on 19 December 2025, GSK entered into an agreement with the US Administration to lower the cost of prescription medicines for American patients and exclude both GSK and ViiV Healthcare from Section 232 tariffs for three years. On 9 April 2026, GSK, ViiV Healthcare, and the US Government entered into a definitive agreement reflecting Section 232 tariff relief through 20 January 2029 (subject to implementation and ongoing compliance). As part of that implementation, GSK and ViiV Healthcare each signed a GENEROUS Model Manufacturer Participation Agreement with the Centers for Medicare and Medicaid Services effective 15 June 2026. With these agreements GSK and ViiV Healthcare have committed certain products to participate in the voluntary GENEROUS Model. GSK and ViiV have also entered into GENEROUS Model Supplemental Rebate Agreements with several interested states and will work with the other states going forward to execute Supplemental Rebate Agreements as requested. Our full year guidance is inclusive of the expected impact of these agreements. Dividend policy The Dividend policy and the expected pay-out ratio remain unchanged. Consistent with this, GSK has declared a dividend for Q3 2026 of 17p per share. GSK's future dividend policy and guidance regarding the expected dividend pay-out in 2026 are provided on page 30. GSK completed the £2 billion share buyback programme announced in FY 2024 in Q2 2026. Exchange rates If exchange rates were to hold at the closing rates on 30 September 2026 ($1.33/£1, €1.17/£1 and Yen 209/£1) for the rest of 2026, the estimated impact on 2026 Sterling turnover growth for GSK would be -1% and if exchange gains or losses were recognised at the same level as in 2025, the estimated impact on 2026 Sterling Core Operating Profit growth for GSK would be -3%. Results presentation A conference call and webcast for investors and analysts of the quarterly results will be hosted by Luke Miels, CEO, at 12:00 GMT (08:00 EDT) on 28 October 2026. Presentation materials will be published on www.gsk.com prior to the webcast and a transcript of the webcast will be published subsequently. Notwithstanding the inclusion of weblinks, information available on the company’s website, or from non GSK sources, is not incorporated by reference into this Results Announcement. Performance: Turnover Turnover Q3 2026 Year to date £m AER% CER% £m AER% CER% HIV 2,116 9 10 6,018 9 10 Respiratory, Immunology & Inflammation (RI&I) 1,139 19 21 3,164 16 18 Oncology 622 22 23 1,703 21 22 Specialty Medicines 3,877 14 15 10,885 13 14 Shingles (Shingrix) 780 (6) (5) 2,694 6 6
Page 3
Meningitis 599 11 12 1,396 10 11 RSV (Arexvy) 195 (22) (24) 452 14 12 Influenza 177 (18) (17) 198 (11) (9) Other Paediatric & Adult Vaccines 832 (1) – 2,276 (6) (5) Vaccines 2,583 (4) (2) 7,016 2 3 Respiratory 1,708 – 1 4,981 (6) (4) Other General Medicines 719 (5) (3) 2,043 (9) (6) General Medicines 2,427 (1) – 7,024 (7) (5) Total 8,887 4 5 24,925 4 5 By Region: US 4,931 8 10 12,976 5 7 Europe 1,928 3 3 6,053 11 8 International 2,028 (4) (3) 5,896 (4) (2) Total 8,887 4 5 24,925 4 5 Financial Performance – Q3 2026 results unless otherwise stated, growth % and commentary at CER. The quarter and YTD adverse currency impact on AERversus CER primarily reflected the strengthening of Sterling against the USD. See page 8 for further details. For product list - see page 50 Q3 2026 Year to dateKey Drivers £m AER%CER% £m AER%CER% SpecialtyMedicinesTotal 3,877 14 15 10,885 13 14Continued growth across disease areas, with strongperformances in HIV, Respiratory, Immunology &Inflammation, and Oncology. HIV 2,116 9 10 6,018 9 10In Q3 LAIs delivered 80% of total HIV growth. Strongunderlying patient demand of +7ppts for Cabenuva, Apretudeand Dovato more than offset mature portfolio decline, withadditional favourable pricing from US channel mix in Q3. USHIV sales increased 14% with LAIs representing 35% of USHIV turnover. Dovato 754 8 9 2,169 13 14Strong demand across US and EU partly offset by theInternational region where the DTG LoE has started to impacttender volumes. Cabenuva 478 34 35 1,299 31 33Contributed >65% of total HIV growth in Q3, with strongdemand across all regions. Apretude 143 19 21 403 30 33Growth driven by continued strong demand in a competitive USlong-acting prevention market. RI&I 1,139 19 21 3,164 16 18Growth driven by Nucala and Exdensur in respiratory andBenlysta in immunology. Nucala 582 17 18 1,676 16 18Sustained double-digit growth largely driven by US andInternational regions, with increased demand across allindications enhanced by COPD launches. Strong US volumegrowth was partially offset by continued pricing pressures. Exdensur 27 – – 56 – –Increasing new patient starts in key growth markets US, Japanand Germany, and geographic expansion with launches acrossother European and International markets. Exdensur is nowlaunched in 8 countries globally. Benlysta 520 16 17 1,402 12 14Strong volume growth in Q3 and YTD, with bio-penetrationrates having increased across many markets. Q3 2026 Year to dateKey Drivers £m AER% CER% £m AER% CER% Oncology 622 22 23 1,703 21 22Increasing patient demand for Jemperli,Ojjaara/Omjjara and Blenrep, partially offsetby a decrease in Zejula. Jideytro, for thetreatment of TKI-pretreated ROS-1 positiveNSCLC, was approved and launched in the USin Q3 2026 with sales of £3 million. Jemperli 273 19 19 753 25 27Continued strong growth in Q3 and YTDacross all regions. US continued to growdouble-digit, which reduced in Q3 as newpatient starts moderated. Strong growthcontinued in Europe and International drivenby launches and reimbursement expansionacross markets. Ojjaara/Omjjara 195 34 35 526 33 35Higher patient uptake across the regions andfrom continued commercial launches acrossEurope and International markets. US volumegrowth in Q3 and YTD was partly offset bycontinuing pricing pressures.
Page 4
Zejula 104 (24) (23) 319 (24) (23) US continues to decline with volume impactedby the 2025 FDA label update and new 2026prior authorisation insurance requirements, andadverse pricing impacts. Europe declined dueto increased competition. Blenrep 50 – – 109 >100 >100US sales driven by patient uptake in bothcommunity and academic settings. Continuedgeographic expansion with launches acrossEurope and International markets. Blenrep isnow launched in 28 countries globally. Q3 2026 Year to dateKey Drivers £m AER%CER% £m AER%CER% VaccinesTotal 2,583 (4) (2) 7,016 2 3Q3 decreases in Arexvy, Shingrix and Influenza partly offset byMeningitis vaccines. YTD growth due to Shingrix andMeningitis vaccines partly offset by Other Paediatric & AdultVaccines. Shingrix 780 (6) (5) 2,694 6 6Q3 decline driven by lower sales in International, primarily China,partly offset by US pricing and inventory build in the quarter.YTD growth was also driven by higher demand in Europe. The cumulative immunisation rate in the US reached 46%, up3ppts compared to 12 months earlier(1). Meningitis 599 11 12 1,396 10 11Highest ever sales quarter with growth delivered by Penmenvycontinued post launch uptake and Bexsero CDC stockpile buildand ordering patterns in the US. YTD growth included outbreak-related demand for Bexsero in International and Europe. Arexvy 195 (22) (24) 452 14 12Q3 decline due to lower market demand, as well as returnsprovision adjustments in the US in Q3 2025, partly offset bygrowth in Europe from uptake in Germany. YTD growthbenefitted from Australian tender deliveries. Influenza 177 (18) (17) 198 (11) (9) Declining due to US competitive pressure and delayed timing ofdeliveries. OtherPaediatric& AdultVaccines 832 (1) – 2,276 (6) (5) Broadly flat as MMR/V vaccine sales decreased due to the one-offsale of bulk antigen in 2025 and lower demand in International,offset by favourable CDC stockpile and channel inventorymovements for Boostrix in the US. YTD decline was impacted bycompetitive pressure for Other Vaccines, particularly Synflorix inInternational. (1) Based on data from IQVIA up until the end of Q2 2026 Q3 2026 Year to dateKey Drivers £m AER%CER% £m AER%CER% GeneralMedicinesTotal 2,427 (1) – 7,024 (7) (5) Broadly stable in the quarter with growth in Trelegy offset bydeclines in the other Respiratory and Other GeneralMedicines products. Decline YTD with Trelegy broadly stableand declines across the broader portfolio. Respiratory 1,708 – 1 4,981 (6) (4) Trelegy increased in Q3 driven by volume and pricingadjustments, broadly stable YTD. Decreases in other respiratoryproducts due to continued competitive pressures and genericerosion. Trelegy 787 7 8 2,208 (2) –Sales grew in Q3 across all regions. US sales in the quarter grewhigh single-digit driven by increased volume and positive pricingadjustments. YTD sales were broadly stable as growth in Europeand International was offset by decreases in the US, wherevolumes remain adversely impacted by Medicare benefit designchanges and continued pricing pressures. OtherGeneralMedicines 719 (5) (3) 2,043 (9) (6) Decrease in growth driven by continued competitive pressuresand generic competition across the portfolio and a reduction incontract manufacturing sales. By Region Q3 2026 Year to dateKey Drivers £m AER% CER% £m AER% CER% US 4,931 8 10 12,976 5 7Specialty Medicines: Q3 +17%, YTD +16%Growth driven largely by patient demand in HIV,Oncology, Benlysta and Nucala. Vaccines: Q3 +2%, YTD +2%Growth primarily driven by favourable pricing andchannel inventory movements for Shingrix, CDCstockpile and channel inventory movements for
Page 5
Boostrix and Penmenvy continued post launchuptake partly offset by lower demand for Arexvy. General Medicines: Q3 +3%, YTD -7%Trelegy growth in the quarter from sales volumeand positive pricing adjustments. YTD, Trelegydeclines as volumes have been impacted byMedicare benefit design changes and continuedpricing pressures. Decreases continued across theother respiratory and Other General Medicineportfolios partially offset in the quarter with priceadjustments to Ventolin and Advair. Europe 1,928 3 3 6,053 11 8Specialty Medicines: Q3 +9%, YTD +9%Growth driven by Oncology, Nucala, Benlysta andHIV. Vaccines: Q3 +2%, YTD +15%Q3 growth driven by Arexvy uptake in Germany,with significant increased demand for Shingrixacross Europe YTD. General Medicines: Q3 -3%, YTD -2%Low single-digit decline, with growth in Trelegyand Anoro more than offset by decreases in otherrespiratory products. International 2,028 (4) (3) 5,896 (4) (2) Specialty Medicines: Q3 +13%, YTD +13%Growth driven by Oncology, Nucala and Benlysta. Vaccines: Q3 -15%, YTD -9%Q3 decline primarily due to lower sales of Shingrix,primarily in China and the one-off sale of MMR/Vbulk antigen in 2025. YTD sales reflect competitivepressure for Other Vaccines, partly offset by growthin Arexvy from Australian tender deliveries. General Medicines: Q3 -2%, YTD -4%Growth in Trelegy and Anoro more than offset bydecreases across other respiratory and OtherGeneral Medicine products, which includedreductions in contract manufacturing income. Financial Performance - Core results Core operating profit growth in Q3 2026 and YTD primarily reflected higher turnover, favourable product and regional mix, ongoing productivity initiatives and supply chain optimisation, higher royalty income, and favourable net legal settlements and expenses in Q1 2026, partly offset by increased investment in R&D and new asset launches. The increase in Core EPS in Q3 2026 and YTD primarily reflected the growth in Core operating profit and the share buyback, partly offset by higher net finance expenses primarily due to Nuvalent, a higher effective tax rate and higher NCIs. Core Results Q3 2026 Year to date £m % AER % CER £m % AER % CER Turnover 8,887 4 5 24,925 4 5 Cost of sales (2,040) (1) – (5,639) (2) (2) % of sales 23.0% (1.1) (1.2) 22.6% (1.4) (1.6) Selling, general and administration (2,155) – 1 (6,329) – 1 % of sales 24.2% (1.0) (1.1) 25.4% (0.9) (1.0) Research and development (1,874) 21 22 (5,088) 14 16 % of sales 21.1% 2.9 2.9 20.4% 1.9 1.9 Royalty income 258 24 24 657 4 3 Core operating profit 3,076 3 5 8,526 5 7 % of sales 34.6% (0.3) (0.1) 34.2% 0.3 0.7 Core net finance expense (197) 49 50 (461) 29 30 Share of after tax profit/(loss) of associates and joint ventures (2) (9) Core profit before taxation 2,877 1 3 8,056 3 6 Taxation (490) 8 9 (1,405) 6 8 Tax rate % 17.0% 17.4% Core profit after taxation 2,387 – 1 6,651 3 6 Core profit attributable to non-controlling interests 198 12 14 562 10 12 Core profit attributable to shareholders2,189 6,089 2,387 – 1 6,651 3 6 Core Earnings per share 54.6p (1) 1 151.6p 4 6 Financial Performance – Q3 2026 results unless otherwise stated, growth % and commentary at CER. See page 7 for Total results financial performancecommentary. In the quarter and YTD, the adverse currency impact on AER versus CER primarily reflected the strengthening of Sterling against the USD. Seepage 8 for further details. Reconciliations between Total results and Core results Q3 2026, Q3 2025, 9 months 2026 and 9 months 2025 are set out on pages 16and 18.
Page 6
Core cost of sales as a percentage of sales decreased in Q3 2026 and YTD primarily due to favourable product and regional mix driven by higher specialty sales and the growth of higher margin Vaccines products YTD, as well as a favourable YTD comparator due to supply chain optimisation charges incurred in Q2 2025. Core SG&A was broadly stable in Q3 2026 and YTD with disciplined investment to support launches for new assets including Blenrep and Exdensur partly offset by ongoing productivity initiatives. The YTD also has net favourability on legal settlements and expenses equivalent to around 1ppt impact. Core R&D investment increased in Q3 2026 and YTD reflecting progression across the portfolio, primarily in Oncology. This included acceleration in work on ADCs Ris-Rez and Mo-Rez, progress on velzatinib for GIST and, following the Nuvalent acquisition, on Jideytro (zidesamtinib), approved by the FDA in the quarter, and neladalkib. In Specialty Medicines, increased investment was driven by efimosfermin acquired in Q3 2025, depemokimab COPD indication and all indications of felcorekibart (the anti-TSLP monoclonal antibody). Growth was partly offset by lower spend on bepirovirsen which was filed in Q1 2026. Investment also increased on clinical trial programmes associated with mRNA seasonal flu vaccines. Core royalty income increased in Q3 2026 and YTD primarily due to higher Kesimpta (1) royalties, partly offset in the YTD by historic royalties recognised in Q2 2025 related to the settlement of an IP dispute. The increase in net finance costs in Q3 2026 and YTD was driven by higher interest expense primarily related to the Nuvalent acquisition, partly offset by a net favourable variance on hedging activities. The effective tax rate on Core profits was broadly in line with expectations for the year. Core NCIs in the quarter and YTD were higher primarily due to higher core profit allocations from ViiV Healthcare. (1) Kesimpta is manufactured by and a trademark of Novartis AG Financial performance - Total results Total operating profit decreased in Q3 2026 primarily due to Major Restructuring charges of £328 million related to the Accelerate Growth programme and lower other net operating income, partly offset by higher Core operating profit. YTD profit also decreased primarily due to higher impairments and higher CCL charges, partly offset by higher other net operating income and Core operating profit. Total EPS decreased in Q3 2026 and YTD primarily due to lower Total operating profit, higher finance expenses, and higher NCIs in Q3, partly offset by the share buyback and a lower effective tax rate. Total Results Q3 2026 Year to date £m % AER % CER £m % AER % CER Turnover 8,887 4 5 24,925 4 5 Cost of sales (2,390) 6 7 (6,531) 3 3 % of sales 26.9% 0.5 0.4 26.2% (0.2) (0.5) Selling, general and administration (2,383) 6 7 (6,704) 4 5 % of sales 26.8% 0.6 0.5 26.9% 0.1 – Research and development (1,983) 17 18 (7,141) 38 39 % of sales 22.3% 2.6 2.5 28.6% 7.1 7.0 Royalty income 258 24 24 657 4 3 Other operating income/(expense) (262) >100 >100 (305) >100 >100 Operating profit 2,127 (18) (16) 4,901 (28) (25) % of sales 23.9% (6.4) (6.1) 19.7% (8.7) (8.2) Net finance expense (190) 35 36 (459) 20 21 Share of after tax profit/(loss) of associates and joint ventures (2) (9) Profit before taxation 1,935 (21) (19) 4,433 (31) (28) Taxation (232) (26) (24) (338) (62) (58) Tax rate % 12.0% 7.6% Profit after taxation 1,703 (21) (19) 4,095 (26) (23) Profit attributable to non-controlling interests 160 22 25 380 (21) (18) Profit attributable to shareholders 1,543 3,715 1,703 (21) (19) 4,095 (26) (23) Earnings per share 38.5p (23) (21) 92.5p (26) (23) Financial Performance – Q3 2026 results unless otherwise stated, growth % and commentary at CER. See page 6 for Core results financial performancecommentary.In the quarter and YTD, the adverse currency impact on AER versus CER primarily reflected the strengthening of Sterling against the USD. See page 8 forfurther details. Reconciliations between Total results and Core results Q3 2026, Q3 2025, 9 months 2026 and 9 months 2025 are set out on pages 16 and 18. Total cost of sales increased in Q3 2026 and YTD due to Major restructuring charges related to the Accelerate Growth programme taken in Q3 and higher impairments in Q2, partly offset by Core cost of sales benefits. Total SG&A increased in the quarter and YTD primarily due to Major restructuring charges related to the Accelerate Growth programme taken in Q3, as well as Nuvalent transaction costs. YTD also included amounts reclassified from the foreign currency translation reserve to the income statement upon the liquidation of a
Page 7
subsidiary, and acquisition and integration costs related to RAPT Therapeutics ("RAPT"). Core SG&A was broadly stable in Q3 2026 and YTD. Total R&D growth in Q3 2026 was driven by Core R&D investment. YTD growth included the impact of higher impairments in Q2 2026 related to camlipixant (£1,334 million) and the termination of assets related to the collaboration with Alector (£371 million). See page 19 for more details. Total royalty income increased in the quarter and YTD driven by Core royalties. Other operating income/(expense) in Q3 2026 included a charge of £289 million (Q3 2025: £280 million) arising from the remeasurement of CCLs, partly offset by net income of £27 million (Q3 2025: £304 million). The YTD included a charge of £1,040 million (YTD 2025: £193 million) principally arising from the remeasurement of CCLs, partly offset by net income of £735 million (YTD 2025: £326 million) primarily related to profit on the sale of the Rockville manufacturing facility and the divestment of linerixibat. See pages 17 and 19 for further details. Net finance costs increased in Q3 2026 and YTD mainly due to Core net finance expenses. The effective tax rate on Total results reflected the different tax effects of the various Adjusting items included in Total results. Issues related to taxation are described in Note 14, ‘Taxation’ in the Annual Report 2025. The Group continues to believe it has made adequate provision for the liabilities likely to arise from periods that are open and not yet agreed by relevant tax authorities. The ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of agreements with relevant tax authorities. The increase in Total NCIs in Q3 was driven by higher core profit allocations from ViiV Healthcare. The YTD decrease primarily reflected higher remeasurement charges on the Shionogi-ViiV CCL. Exchange rates and impact on results GSK operates in many countries and earns revenues and incurs costs in many currencies. The results of the Group, as reported in Sterling, are affected by movements in exchange rates between Sterling and other currencies. Average exchange rates, as modified by specific transaction rates for large transactions, prevailing during the period, are used to translate the results and cash flows of overseas subsidiaries, associates and joint ventures into Sterling. Period-end rates are used to translate the net assets of those entities. The currencies which most influenced these translations and the relevant exchange rates were: Q3 2026 Q3 2025 YTD 2026 YTD 2025 2025 Average rates: US$/£ 1.34 1.33 1.34 1.31 1.31 Euro/£ 1.17 1.16 1.16 1.18 1.17 Yen/£ 213 198 213 195 198 Period-end rates: US$/£ 1.33 1.34 1.33 1.34 1.35 Euro/£ 1.17 1.14 1.17 1.14 1.15 Yen/£ 209 199 209 199 211 In Q3 2026 and YTD, the adverse currency impact primarily reflected the strengthening of Sterling against the US Dollar, particularly in Q1 2026, as well as the Yen and emerging market currencies, partly offset in the YTD by strengthening of the Euro. Exchange movements on the settlement of intercompany transactions had a minimal impact on Total and Core EPS in the quarter and YTD. Cash generation Cash flow Q3 2026£m Q3 2025£m 9 months 2026£m 9 months 2025£m Cash generated from operations (£m) 3,122 2,520 7,378 6,254 Total net cash inflow/(outflow) from operating activities (£m)2,809 2,222 6,640 5,463 Free cash inflow/(outflow)* (£m) 2,078 1,246 4,887 3,069 Free cash flow growth/(decline) (%) 67% (6%) 59% 58% Free cash flow conversion* (%) >100% 62% >100% 60% Total net debt** (£m) 20,739 14,444 20,739 14,444 * Free cash flow and free cash flow conversion are defined on page 43. Free cash flow is analysed on page 34. ** Total net debt is defined on page 44. Net debt is analysed on page 34. Q3 2026 Cash generated from operations for the quarter was £3,122 million (Q3 2025: £2,520 million). The increase primarily reflected higher Core operating profit and favourable timing and movements on trade receivables, payables and returns and rebates, partly offset by an adverse exchange rate impact. The increase also reflected a
Page 8
favourable comparator to £565 million Zantac settlement payments in Q3 2025, partly offset by the £268 million cash settlement from CureVac received in Q3 2025. Total contingent consideration cash payments in the quarter were £435 million (Q3 2025: £326 million). £346 million (Q3 2025: £321 million) of these were recognised in cash flows from operating activities, including cash payments made to Shionogi & Co. Ltd ("Shionogi") of £342 million (Q3 2025: £306 million). Free cash inflow was £2,078 million for the quarter (Q3 2025: £1,246 million). The increase was primarily driven by higher cash generated from operations and lower capital expenditure on intangible assets. 9 months 2026 Cash generated from operations was £7,378 million (9 months 2025: £6,254 million). The increase reflected higher Core operating profit, favourable timing and movements on trade receivables and payables, partly offset by an adverse exchange rate impact, as well as adverse timing and movements on returns and rebates. The increase also reflected a favourable comparator to £688 million Zantac settlement payments in YTD 2025, partly offset by the cash settlement from CureVac (of which the majority was received in 2025). Total contingent consideration cash payments in 9 months 2026 were £1,191 million (9 months 2025: £1,000 million). £1,095 million (9 months 2025: £989 million) of these were recognised in cash flows from operating activities, including cash payments made to Shionogi of £1,052 million (9 months 2025: £956 million). Free cash inflow was £4,887 million for 9 months 2026 (9 months 2025: £3,069 million). The increase was driven by higher cash generated from operations, lower capital expenditure on intangible assets, higher proceeds from the sale of intangible assets, including the divestment of linerixibat, and the special dividend of $250 million (£187 million) related to the ViiV shareholding restructure. Total Net debt At 30 September 2026, net debt was £20,739 million, compared with £14,453 million at 31 December 2025, comprising gross debt of £23,701 million and cash and liquid investments of £2,962 million. See net debt information on page 34. Net debt increased by £6,286 million primarily due to net acquisition costs for Nuvalent £7,143 million, RAPT £1,404 million and 35Pharma Inc. £700 million, dividends paid to shareholders of £2,052 million, shares purchased as part of the share buyback programme (completed in June 2026) of £634 million and an exchange loss on net debt of £85 million. This was partly offset by primarily the free cash inflow of £4,887 million and £386 million related to the disposal of the Rockville site including proceeds and a reduction in lease liabilities. At 30 September 2026, GSK had short-term borrowings (including overdrafts and lease liabilities) repayable within 12 months of £2,001 million and £2,978 million repayable in the subsequent year. Contents Page Q3 2026 pipeline highlights 11 Responsible business 13 Total and Core results 14 Income statement 20 Statement of comprehensive income 21 Balance sheet 22 Statement of changes in equity 23 Cash flow statement 24 Sales tables 25 Segment information 28 Legal matters 29 Returns to shareholders 30 Additional information 31 R&D commentary 35 Reporting definitions 43 Guidance and outlooks, assumptions and cautionary statements 45 Independent Auditor's review report to GSK plc 47 Glossary of terms 49 Contacts GSK plc (LSE/NYSE:GSK) is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com. GSK enquiries: Media Tim Foley +44 (0) 7780 494750 (London) Kathleen Quinn +1 202 603 5003 (Washington)
Page 9
Investor Relations James Dodwell +44 (0) 7881 269066 (London) Mick Readey +44 (0) 7990 339653 (London) Joanna Tuplin +44 (0) 7788 351650 (London) Sam Piper +44 (0) 7824 525779 (London) Dan Smith +44 (0) 7823 523885 (London) Jeff McLaughlin +1 215 751 7002 (Philadelphia) Frannie DeFranco +1 215 751 3126 (Philadelphia) Registered in England & Wales: No. 3888792 Registered Office: 79 New Oxford Street London, WC1A 1DG Q3 2026 pipeline highlights (since 28 July 2026) Medicine/vaccine Trial (indication, presentation) Event Regulatory approvals or other regulatory actions Jemperli Stage II and stage III microsatellite instability- high (MSI-H) / mismatch repair deficient (dMMR) locally advanced rectal cancer Regulatory approval (US) Hibsago Chronic Hepatitis B (CHB) Regulatory approval (JP, US) Arexvy Respiratory Syncytial Virus (RSV) Immunocompromised (IC) adults aged 18 years and older Regulatory approval (US) Shingrix Shingles (prefilled syringe presentation)Regulatory approval (JP) Regulatory submissions or acceptances Ventolin Low carbon MDI (asthma) Regulatory submission (EU) Jemperli AZUR-1 (rectal cancer) Regulatory submission (US) Phase III data readouts or other significant events Jideytro ARROS-1 (treatment naive ROS 1+non-small cell lung cancer) Positive phase I/II (registrational) data readout Cabenuva CROWN (HIV, unsuppressed) Positive phase IIIb topline data readout Zejula GLIOFOCUS (glioblastoma) Orphan Drug Designation (EU) Double-target HA-NA seasonal flu Seasonal mRNA influenza virus vaccine candidate Fast Track Designation (US) RSV/hMPV investigational combination vaccine Respiratory Syncytial Virus/Human Metapneumovirus (RSV/hMPV) Fast Track Designation (US) Anticipated pipeline milestones Timing Medicine/vaccine Trial (indication, presentation) Event H2 2026 Exdensur OCEAN (eosinophilic granulomatosis with polyangiitis) Phase III data readout neladalkib Non-small cell lung cancer (pre- treated ALK+) Regulatory decision (US) Jideytro Non-small cell lung cancer (treatment naïve ROS 1+) Regulatory submission (US) cabotegravir 3x a year prevention (HIV)Phase IIb (pivotal) data readout cabotegravir 3x a year prevention (HIV)Regulatory submission (US) H1 2027 Exdensur OCEAN (eosinophilic granulomatosis with polyangiitis) Regulatory submission (US, EU, CN, JP) Ventolin Low carbon MDI (asthma) Regulatory decision (EU) Ventolin Low carbon MDI (asthma) Regulatory submission (US)
Page 10
Jemperli AZUR-1 (rectal cancer) Regulatory submission (JP) cabotegravir 3x a year prevention (HIV)Regulatory decision (US) Arexvy RSV, adults aged 18-59 Phase III data readout (CN) Bexsero Meningococcal B (infants) Regulatory submission (US) bepirovirsen B-WELL 1/2 (chronic hepatitis B)Regulatory decision (EU, CN) GSK'116 (varicella vaccine) Varicella new seed, individuals 12 months of age and older Phase III data readout neladalkib Non-small cell lung cancer (pre- treated ALK+) Regulatory submission (EU) Jideytro Non-small cell lung cancer (pre- treated ROS 1+) Regulatory submission (EU) Timing Medicine/vaccine Trial (indication, presentation) Event H2 2027 Exdensur OCEAN (eosinophilic granulomatosis with polyangiitis)Regulatory decision (US, JP) Jemperli AZUR-1 (rectal cancer) Regulatory submission (EU, CN) Jemperli AZUR-1 (rectal cancer) Regulatory decision (EU) Ris-Rez EMBOLD SCLC-301 (small cell lung cancer)Phase III data readout velzatinib GIST - 1L or 2L therapy for advanced gastrointestinal stromal tumors Phase III data readout Jideytro Non-small cell lung cancer (treatment naïve ROS1+)Regulatory decision (US) cabotegravir + rilpivirineCUATRO, 3x a year treatment (HIV) Phase III data readout cabotegravir + rilpivirineCUATRO, 3x a year treatment (HIV) Regulatory submission (US) Arexvy RSV, adults aged 18-59 Regulatory submission (CN) Arexvy RSV, adults aged 60+ Regulatory decision (CN) Bexsero Meningococcal B (infants) Regulatory decision (US) GSK'116 (varicella vaccine) Varicella new seed, individuals 12 months of age and older Regulatory submission (US) Refer to pages 35 to 42 for further details on several key medicines and vaccines in development by therapy area. Progress on areas for responsible business Being a responsible business is a fundamental part of GSK’s strategy and supports long-term performance. Annual progress against GSK’s responsible business priorities is detailed in the Annual (1) and Responsible Business (2) Reports with incremental updates shared each quarter. Highlights below include activity since Q2 2026 results. Access • In October, ViiV Healthcare announced(3) an agreement with Axmed to expand access to HIV medicines in more than 50 middle-income countries. With most new HIV cases reported in low- and middle-income countries, expanding choice in HIV care options remains a key priority. This agreement aims to offer a simpler route for local governments and healthcare institutions to access more choice in HIV care to support countries’ HIV response. Global health and health security • Dengue remains a major unmet global health challenge with hundreds of millions of infections estimated each year and limited treatment options. In August, Chugai and GSK signed(4) an exclusive license agreement to develop a preclinical anti-dengue virus antibody which, if successful, could help manage dengue fever and other flavivirus infections. • With the growing threat of drug-resistance in malaria treatment, there is an urgent need for continued innovation. Through GSK’s partnership with Medicines for Malaria Venture, a potential new phase II malaria drug, GSK701, has shown(5) to be a promising candidate for uncomplicated malaria that could help meet a need for new medicines. • A new equitable access agreement between Gavi, UNICEF and Bharat Biotech (BBIL), announced(6) in October 2026 for the GSK-developed malaria vaccine, RTS,S/AS01, will cut the price of the vaccine by 40%, generating around $50 million in savings to child immunisation programmes (2027-29), and support vaccination of an estimated 1 million more children. The agreement follows investment by GSK and BBIL in new, higher-output manufacturing facilities, product development and technology transfer to expand and strengthen supply at a lower cost. Environment • All five of GSK’s manufacturing sites in areas experiencing water-stress across India, Pakistan and Algeria have now achieved Alliance for Water Stewardship (AWS) certification, following a rigorous independent audit. This
Page 11
certification recognises the work our sites are doing to manage water responsibly, from how we use water in our operations to how we understand and address water risks in the communities where we operate. • In September, GSK announced(7) a new eight-year investment in regenerative agriculture carbon credits in northern India. This agreement with Earthly aims to deliver both emissions reductions and carbon removals, whilst delivering wider health and local community benefits. The investment supports GSK’s pathway to net zero impact on climate. By 2030, GSK aims to reduce its carbon emissions by 80% (from a 2020 baseline), with the remaining 20% covered through investment in high-quality nature protection and restoration projects. Responsible Business rating performance Detailed below is how GSK performs in key Responsible Business ratings*. External benchmarkCurrent score/ranking Previous score/ranking Comments Access to Medicines Index 3.72 4.06 Second in the Index, updated bi-annually, current results from November 2024. Scores range from 1 to 5, with 5 being the highest (best) score Antimicrobial resistance benchmark 77% 84% Led the benchmark since its inception in 2018; Current ranking updated March 2026 CDP Climate ChangeA A Updated annually, current scores updated December 2025 (for supplier engagement, May 2026)CDP Water SecurityA A CDP supplier engagement rating Leader Leader Sustainalytics Low risk Low risk 2nd percentile in pharma subindustry group. Current rating as at October 2026 ISS Corporate RatingB+ B+ Ranked 1st in our peer group. Last profile update July 2026 FTSE4Good Member Member Member since 2004, latest review in July 2026 *GSK’s Responsible Business ratings are regularly reviewed to ensure the external benchmarks listed remain high quality, appropriate and relevant to investors.The outcome of these reviews may lead to changes on which ratings are included in the table above – last updated July 2026 (1) https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2025 (2) https://www.gsk.com/media/di5bk40q/responsible-business-report.pdf (3) https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2026/october/axmed-partner-to-expand-access-to-hiv-medicines/ (4) https://www.chugai-pharm.co.jp/english/news/detail/20260818113000_1263.html (5) https://www.mmv.org/news-resources-search/new-malaria-drug-candidate-shows-early-promise-human-study (6) https://www.gavi.org/news/media-room/gavi-and-unicef-secure-lower-malaria-vaccine-price-saving-us-50-million-childhood (7) https://earthly.org/blog/gsk-investment-in-regenerative-agriculture-carbon-credits-reduce-greenhouse-gas-emissions-and-air-pollution-supporting-human-health Total and Core results Total reported results represent the Group’s overall performance. GSK uses a number of non-IFRS measures to report the performance of its business. Core results and other non- IFRS measures may be considered in addition to, but not as a substitute for, or superior to, information presented in accordance with IFRS. Core results are defined below and other non-IFRS measures are defined on pages 43 and 44. GSK believes that Core results, when considered together with Total results, provide investors, analysts and other stakeholders with helpful complementary information to understand better the financial performance and position of the Group from period to period, and allow the Group’s performance to be more easily compared against the majority of its peer companies. These measures are also used by management for planning and reporting purposes. They may not be directly comparable with similarly described measures used by other companies. GSK encourages investors and analysts not to rely on any single financial measure but to review GSK’s quarterly results announcements, including the financial statements and notes, in their entirety. GSK is committed to continuously improving its financial reporting, in line with evolving regulatory requirements and best practice. In line with this practice, GSK expects to continue to review and refine its reporting framework. Core results exclude the following items in relation to our operations from Total results, together with the tax effects of all of these items: • amortisation of intangible assets (excluding computer software and capitalised development costs) to reflect the Group's performance excluding the effect of acquisitions • impairment of intangible assets (excluding computer software) and goodwill to reflect the Group's performance excluding the effect of acquisitions • major restructuring and integration costs, which are: – cash and non-cash costs such as impairment of tangible assets and computer software, relating to Major restructuring programmes which are specific Board-approved programmes that are structural and of significant scale, where the costs of individual or related projects within such programmes exceed £25 million; or – costs that relate to restructuring and integration following a significant acquisition.
Page 12
Costs for other ordinary course, smaller-scale restructuring and integration are retained within both Total and Core results • transaction-related accounting or other adjustments related to significant acquisitions • proceeds and costs of disposal of associates, products and businesses; significant settlement income; Significant legal charges (net of insurance recoveries) and expenses on the settlement of litigation and government investigations; other operating income other than royalty income, and other items including amounts reclassified from the foreign currency translation reserve to the income statement upon the liquidation of a subsidiary where the amount exceeds £25 million As Core results include the benefits of Major restructuring programmes but exclude significant costs (such as Significant legal charges and expenses, major restructuring costs and transaction items) they should not be regarded as a complete picture of the Group’s financial performance, which is presented in Total results. The exclusion of other Adjusting items may result in Core earnings being materially higher or lower than Total earnings. In particular, when significant impairments, restructuring charges and legal costs are excluded, Core earnings will be higher than Total earnings. GSK has undertaken a number of Major restructuring programmes in response to significant changes in the Group’s trading environment or overall strategy or following material acquisitions. Within the Pharmaceuticals sector, the highly regulated manufacturing operations and supply chains and long lifecycle of the business mean that restructuring programmes, particularly those that involve the rationalisation or closure of manufacturing or R&D sites are likely to take several years to complete. Costs, both cash and non-cash, of these programmes are provided for as individual elements are approved and meet the accounting recognition criteria. As a result, charges may be incurred over a number of years following the initiation of a Major restructuring programme. Significant legal charges and expenses are those arising from the settlement of litigation or government investigations that are not in the normal course and materially larger than more regularly occurring individual matters. They also include certain major legacy matters. Reconciliations between Total and Core results, providing further information on the key Adjusting items, are set out on pages 16 and 18. GSK provides earnings guidance to the investor community on the basis of Core results. This is in line with peer companies and expectations of the investor community, supporting easier comparison of the Group’s performance with its peers. GSK is not able to give guidance for Total results as it cannot reliably forecast certain material elements of the Total results, particularly the future fair value movements on contingent consideration and put options that can and have given rise to significant adjustments driven by external factors such as currency and other movements in capital markets. ViiV Healthcare ViiV Healthcare is a subsidiary of the Group and 100% of its operating results (turnover, operating profit, profit after tax) are included within the Group income statement. On 19 January 2026, GSK reached agreement with Pfizer and Shionogi for the 11.7% economic interest in ViiV Healthcare held by Pfizer to be replaced with an investment by Shionogi. On 31 March 2026, the transaction completed and Shionogi increased its economic interest to 21.7% and GSK maintained its 78.3% economic interest. ViiV Healthcare issued new shares to Shionogi for consideration of $2.125 billion, and cancelled Pfizer’s holding in ViiV Healthcare, returning $1.875 billion to Pfizer. GSK received a special dividend of $0.250 billion (£187 million). Further, on completion GSK extinguished the Pfizer put option liability through retained earnings. The put option liability was £822 million as at 31 December 2025 and was remeasured immediately prior to completion, on the same methodology as at 31 December 2025, with the £33 million change in the liability recognised as an Adjusting item through other operating income/(expense). Earnings for the year are allocated to the two shareholders of ViiV Healthcare on the basis of their respective equity shareholdings (GSK 78.3% and Shionogi 21.7%) and their entitlement to preferential dividends, which are determined by the performance of certain products attributable to each shareholder. As the relative performance of these products changes over time, the proportion of the overall earnings allocated to each shareholder also changes. In particular, the increasing proportion of sales of dolutegravir and cabotegravir-containing products has a favourable impact on the proportion of the preferential dividends that is allocated to GSK. Adjusting items are allocated to shareholders based on their equity interests. GSK was entitled to approximately 83% of the Total earnings and 83% of the Core earnings of ViiV Healthcare for 2025. As consideration for the acquisition of Shionogi’s interest in the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi received the 10% equity stake in ViiV Healthcare and ViiV Healthcare also agreed to pay additional future cash consideration to Shionogi, contingent on the future sales performance of the products being developed by that joint venture, dolutegravir and cabotegravir. Under IFRS 3 ‘Business combinations’, GSK was required to provide for the estimated fair value of this contingent consideration at the time of acquisition and is required to update the liability to the latest estimate of fair value at each subsequent period end. The liability for the contingent consideration recognised in the balance sheet at the date of acquisition was £659 million. Subsequent remeasurements are reflected within other operating income/(expense) and within Adjusting items in the income statement in each period. Cash payments to settle the contingent consideration are made to Shionogi by ViiV Healthcare each quarter, based on the actual sales performance and other income of the relevant products in the previous quarter. These payments reduce the balance sheet liability and hence are not recorded in the income statement. The cash payments made to Shionogi by ViiV Healthcare in the nine months ended 30 September 2026 were £1,052 million.
Page 13
As the liability is required to be recorded at the fair value of estimated future payments, there is a significant timing difference between the charges that are recorded in the Total income statement to reflect movements in the fair value of the liability and the actual cash payments made to settle the liability. Further explanation of the acquisition-related arrangements with ViiV Healthcare is set out on pages 86 and 87 of the Annual Report 2025. The reconciliations between Total results and Core results for Q3 2026 and Q3 2025 are set out below. Three months ended 30 September 2026 Totalresults£m Intangibleassetamort-isation£m Intangibleassetimpair-ment£m Majorrestruc-turingandintegration£m Trans-action-related£m Divest-ments,Significantlegal andotheritems£m Coreresults£m Turnover 8,887 8,887 Cost of sales (2,390) 190 150 10 (2,040) Gross profit 6,497 190 150 10 6,847 Selling, general and administration (2,383) 149 60 19 (2,155) Research and development (1,983) 30 33 46 (1,874) Royalty income 258 258 Other operating income/(expense) (262) 289 (27) – Operating profit 2,127 220 33 345 349 2 3,076 Net finance expense (190) (7) (197) Share of after tax profit/(loss) of associates andjoint ventures (2) (2) Profit before taxation 1,935 220 33 345 349 (5) 2,877 Taxation (232) (48) (7) (56) (89) (58) (490) Tax rate % 12.0% 17.0% Profit after taxation 1,703 172 26 289 260 (63) 2,387 Profit attributable to non-controlling interests 160 38 198 Profit/(loss) attributable to shareholders 1,543 172 26 289 222 (63) 2,189 1,703 172 26 289 260 (63) 2,387 Earnings per share 38.5p 4.3p 0.7p 7.2p 5.5p (1.6p) 54.6p Weighted average number of shares (millions) 4,009 4,009 Three months ended 30 September 2025 Totalresults£m Intangibleassetamort-isation£m Intangibleassetimpair-ment£m Majorrestruc-turingandintegration£m Trans-action-related£m Divest-ments,Significantlegal andotheritems£m Coreresults£m Turnover 8,547 8,547 Cost of sales (2,258) 175 19 5 (2,059) Gross profit 6,289 175 19 5 6,488 Selling, general and administration (2,239) 38 39 3 (2,159) Research and development (1,689) 23 112 2 (1,552) Royalty income 208 208 Other operating income/(expense) 24 (1) 280 (303) – Operating profit 2,593 198 112 58 319 (295) 2,985 Net finance expense (141) 9 (132) Share of after tax profit/(loss) of associates andjoint ventures 4 (9) (5) Profit before taxation 2,456 198 112 58 319 (295) 2,848 Taxation (312) (29) (28) (14) (76) 4 (455)
Page 14
Tax rate % 12.7% 16.0% Profit after taxation 2,144 169 84 44 243 (291) 2,393 Profit attributable to non-controlling interests 131 45 176 Profit/(loss) attributable to shareholders 2,013 169 84 44 198 (291) 2,217 2,144 169 84 44 243 (291) 2,393 Earnings per share 49.9p 4.2p 2.1p 1.1p 4.9p (7.2p) 55.0p Weighted average number of shares (millions) 4,034 4,034 Adjusting items Q3 2026 Intangible asset impairments There were no significant intangible asset impairments in the quarter. Major restructuring and integration Charges of £345 million (Q3 2025: £58 million) were incurred relating to ongoing projects categorised as Major restructuring programmes and integration costs, analysed as follows: Q3 2026 Q3 2025 Cash£m Non-cash£m Total£m Cash£m Non-cash£m Total£m Accelerate Growth programme 318 10 328 – – – Significant acquisitions 15 – 15 4 – 4 Legacy programmes 1 1 2 50 4 54 334 11 345 54 4 58 Accelerate Growth programme To accelerate R&D and capture the growth and value the late-stage portfolio offers, in Q3 2026 GSK initiated a new “Accelerate Growth” programme. This 3-year programme has two objectives: (1) Simplify, and match GSK’s organisation and cost base to its evolving product portfolio, notably in Specialty Medicines (2) Enable the reallocation of GSK’s capital and resources to the late-stage pipeline and to R&D. The Accelerate Growth programme is targeting £1.9 billion of annual savings, to be fully realised by 2029, for expected total costs of £2.4 billion, of which £2.1 billion is expected to be cash costs. Savings will be primarily reinvested in R&D, including business development activity, with a portion also used to strengthen operating margin in the period related to LoE for dolutegravir (2028-2030). The majority of the cost charges will be in 2026 and 2027. Integration costs of significant acquisitions relate predominantly to integration activities for Nuvalent Inc. acquired in Q3 2026 and RAPT acquired in Q1 2026, with smaller incremental costs attributed to earlier acquisitions. Transaction-related adjustments Transaction-related adjustments resulted in a net charge of £349 million (Q3 2025: £319 million), the majority of which related to charges/(credits) for the remeasurement of contingent consideration liabilities. Charge/(credit) Q3 2026£m Q3 2025£m Contingent consideration on former Shionogi-ViiV Healthcare joint venture (including Shionogi preferential dividends) 240 249 ViiV Healthcare put options and Pfizer preferential dividends – (7) Contingent consideration on former Novartis Vaccines business 28 25 Contingent consideration on acquisition of Affinivax 5 10 Other contingent consideration 16 3 Other adjustments 60 39 Total transaction-related charges/(credits) 349 319 The £240 million charge relating to the contingent consideration for the former Shionogi-ViiV Healthcare joint venture represented an increase in the valuation of the contingent consideration due to Shionogi driven by updated sales forecasts and net other remeasurements of £144 million and the unwind of the discount for £96 million. Other adjustments of £60 million primarily related to Nuvalent transaction costs. Divestments, Significant legal charges, and other items
Page 15
Divestments, Significant legal charges, and other items included net other operating income of £27 million (Q3 2025: £303 million). Q3 2025 included the £268 million ($370 million) settlement from CureVac. Legal charges provide for all significant legal matters and are not broken out separately by litigation or investigation. The reconciliations between Total results and Core results for 9 months 2026 and 9 months 2025 are set out below. Nine months ended 30 September 2026 Totalresults£m Intangibleassetamort-isation£m Intangibleassetimpair-ment£m Majorrestruc-turingandintegration£m Trans-action-related£m Divest-ments,Significantlegal andotheritems£m Coreresults£m Turnover 24,925 24,925 Cost of sales (6,531) 524 190 156 22 (5,639) Gross profit 18,394 524 190 156 22 19,286 Selling, general and administration (6,704) 174 79 122 (6,329) Research and development (7,141) 81 1,910 62 (5,088) Royalty income 657 657 Other operating income/(expense) (305) 1,040 (735) – Operating profit 4,901 605 2,100 392 1,119 (591) 8,526 Net finance expense (459) (2) (461) Share of after tax profit/(loss) of associates andjoint ventures (9) (9) Profit before taxation 4,433 605 2,100 392 1,119 (593) 8,056 Taxation (338) (131) (502) (66) (290) (78) (1,405) Tax rate % 7.6% 17.4% Profit after taxation 4,095 474 1,598 326 829 (671) 6,651 Profit attributable to non-controlling interests 380 182 562 Profit/(loss) attributable to shareholders 3,715 474 1,598 326 647 (671) 6,089 4,095 474 1,598 326 829 (671) 6,651 Earnings per share 92.5p 11.8p 39.8p 8.1p 16.1p (16.7p) 151.6p Weighted average number of shares (millions) 4,015 4,015 Nine months ended 30 September 2025 Totalresults£m Intangibleassetamort-isation£m Intangibleassetimpair-ment£m Majorrestruc-turingandintegration£m Trans-action-related£m Divest-ments,Significantlegal andotheritems£m Coreresults£m Turnover 24,049 24,049 Cost of sales (6,360) 546 30 13 (5,771) Gross profit 17,689 546 30 13 18,278 Selling, general and administration (6,449) 54 48 35 (6,312) Research and development (5,175) 65 652 7 (4,451) Royalty income 634 634 Other operating income/(expense) 133 193 (326) – Operating profit 6,832 611 652 91 241 (278) 8,149 Net finance expense (383) 25 (358) Share of after tax profit/(loss) of associates andjoint ventures 2 (9) (7) Profit before taxation 6,451 611 652 91 241 (262) 7,784 Taxation (889) (134) (163) (22) (134) 14 (1,328) Tax rate % 13.8% 17.1%
Page 16
Profit after taxation 5,562 477 489 69 107 (248) 6,456 Profit attributable to non-controlling interests 482 31 513 Profit/(loss) attributable to shareholders 5,080 477 489 69 76 (248) 5,943 5,562 477 489 69 107 (248) 6,456 Earnings per share 125.1p 11.7p 12.0p 1.7p 1.9p (6.1p) 146.3p Weighted average number of shares (millions) 4,062 4,062 Adjusting items 9 months 2026 Intangible asset impairments YTD 2026 impairments of £2,100 million (YTD 2025: £652 million) primarily related to camlipixant £1,334 million in Q2 2026 following GSK's decision not to progress further development of camlipixant in RCC, based on the aggregate data from the CALM-1 and CALM-2 phase III trials. In addition, a full impairment of £371 million was recognised in Q2 2026 following the termination of assets under the Alector collaboration, driven by the outcome of clinical trials. Major restructuring and integration Charges of £392 million (YTD 2025: £91 million) were incurred relating to ongoing projects categorised as Major restructuring programmes, analysed as follows: 9 months 2026 9 months 2025 Cash£m Non-cash£m Total£m Cash£m Non-cash£m Total£m Accelerate Growth programme 318 10 328 – – – Significant acquisitions 59 – 59 12 – 12 Legacy programmes 3 2 5 60 19 79 380 12 392 72 19 91 Details of the Accelerate Growth programme are provided on page 17. The Significant acquisitions programme incurred cash charges of £59 million primarily from integration activities for Nuvalent Inc. acquired in Q3 2026 and RAPT acquired in Q1 2026, with smaller incremental costs attributed to earlier acquisitions. Transaction-related adjustments Transaction-related adjustments resulted in a net charge of £1,119 million (9 months 2025: £241 million), the majority of which related to charges/(credits) for the remeasurement of contingent consideration liabilities. Charge/(credit) 9 months 2026£m 9 months 2025£m Contingent consideration on former Shionogi-ViiV Healthcare joint venture (including Shionogi preferential dividends) 920 161 ViiV Healthcare put options and Pfizer preferential dividends (33) (96) Contingent consideration on former Novartis Vaccines business 28 134 Contingent consideration on acquisition of Affinivax 12 (16) Other contingent consideration 113 10 Other adjustments 79 48 Total transaction-related charges 1,119 241 The £920 million charge relating to the contingent consideration for the former Shionogi-ViiV Healthcare joint venture represented an increase in the valuation of the contingent consideration due to Shionogi, driven by updated sales forecasts and net other remeasurements of £631 million and the unwind of the discount for £289 million. Other adjustments of £79 million primarily related to Nuvalent transaction costs in Q3 2026. Divestments, Significant legal charges, and other items Divestments, Significant legal charges, and other items included net other operating income of £735 million (YTD 2025: £326 million) primarily related to profit on the sale of the Rockville manufacturing facility, including £375m reclassified from the foreign currency translation reserve to the income statement on disposal of the related subsidiary, and proceeds from the divestment of linerixibat. This was partly offset by amounts reclassified from the foreign currency translation reserve to the income statement upon the liquidation of subsidiaries. YTD 2025 included the £268 million ($370 million) settlement from CureVac. Legal charges provide for all significant legal matters and are not broken out separately by litigation or investigation. Financial information
Page 17
Income statement Q3 2026£m Q3 2025£m 9 months 2026£m 9 months 2025£m TURNOVER 8,887 8,547 24,925 24,049 Cost of sales (2,390) (2,258) (6,531) (6,360) Gross profit 6,497 6,289 18,394 17,689 Selling, general and administration (2,383) (2,239) (6,704) (6,449) Research and development (1,983) (1,689) (7,141) (5,175) Royalty income 258 208 657 634 Other operating income/(expense) (262) 24 (305) 133 OPERATING PROFIT 2,127 2,593 4,901 6,832 Finance income 29 26 109 130 Finance expense (219) (167) (568) (513) Share of after tax profit/(loss) of associates and jointventures (2) 4 (9) 2 PROFIT BEFORE TAXATION 1,935 2,456 4,433 6,451 Taxation (232) (312) (338) (889) Tax rate % 12.0% 12.7% 7.6% 13.8% PROFIT AFTER TAXATION 1,703 2,144 4,095 5,562 Profit attributable to non-controlling interests 160 131 380 482 Profit attributable to shareholders 1,543 2,013 3,715 5,080 1,703 2,144 4,095 5,562 EARNINGS PER SHARE 38.5p 49.9p 92.5p 125.1p Diluted earnings per share 37.9p 49.1p 91.1p 123.0p Statement of comprehensive income Q32026£m Q32025£m 9 months2026£m 9 months2025£m Total profit for the period 1,703 2,144 4,095 5,562 Items that may be reclassified subsequently to income statement: Exchange movements on overseas net assets and net investment hedges (21) 25 (103) 292 Reclassification of exchange movements on liquidation or disposal of overseassubsidiaries and associates – (1) (266) (9) Fair value movements on cash flow hedges 135 23 173 (33) Cost of hedging 3 3 – 12 Reclassification of cash flow hedges to income statement 12 (19) (3) 29 Deferred tax on fair value movements on cash flow hedges (7) (1) (8) (1) 122 30 (207) 290 Items that will not be reclassified to income statement: Exchange movements on overseas net assets of non-controlling interests (2) 9 1 (14) Share of the other comprehensive income of associates and joint ventures 4 – 48 – Fair value movements on equity investments 2 115 (54) 81 Tax on fair value movements on equity investments 1 (10) (1) (14) Fair value movements on cash flow hedges 4 – 8 – Remeasurement gains/(losses) on defined benefit plans 40 58 407 132 Tax (charge)/credit on remeasurement of defined benefit plans (8) (15) (97) (31) 41 157 312 154 Other comprehensive income/(expense) for the period 163 187 105 444
Page 18
Total comprehensive income for the period 1,866 2,331 4,200 6,006 Total comprehensive income for the period attributable to: Shareholders 1,708 2,191 3,819 5,538 Non-controlling interests 158 140 381 468 1,866 2,331 4,200 6,006 Balance sheet 30 September 2026£m 31 December 2025£m ASSETS Non-current assets Property, plant and equipment 9,431 9,322 Right of use assets 691 726 Goodwill 8,216 7,018 Other intangible assets 25,172 16,748 Investments in associates and joint ventures 49 89 Other investments 814 1,037 Deferred tax assets 6,735 6,520 Derivative financial instruments 54 – Other non-current assets 2,642 2,148 Total non-current assets 53,804 43,608 Current assets Inventories 6,300 5,924 Current tax recoverable 302 288 Trade and other receivables 8,223 7,471 Derivative financial instruments 103 121 Liquid investments 28 9 Cash and cash equivalents 2,934 3,397 Assets held for sale 5 300 Total current assets 17,895 17,510 TOTAL ASSETS 71,699 61,118 LIABILITIES Current liabilities Short-term borrowings (2,001) (3,012) Contingent consideration liabilities (1,318) (1,348) Trade and other payables (15,633) (15,381) Derivative financial instruments (164) (75) Current tax payable (678) (498) Short-term provisions (926) (938) Liabilities relating to assets held for sale – (139) Total current liabilities (20,720) (21,391) Non-current liabilities Long-term borrowings (21,700) (14,708) Deferred tax liabilities (1,670) (291) Pensions and other post-employment benefits (1,552) (1,687) Derivative financial instruments (101) (67) Other provisions (751) (610) Contingent consideration liabilities (5,311) (5,385) Other non-current liabilities (1,532) (1,023) Total non-current liabilities (32,617) (23,771) TOTAL LIABILITIES (53,337) (45,162) NET ASSETS 18,362 15,956 EQUITY Share capital 1,349 1,349 Share premium account 3,507 3,498 Retained earnings 12,458 10,209 Other reserves 1,440 1,321 Shareholders’ equity 18,754 16,377 Non-controlling interests (392) (421) TOTAL EQUITY 18,362 15,956 Statement of changes in equity
Page 19
Sharecapital£m Sharepremium£m Retainedearnings£m Otherreserves£m Share-holder’sequity£m Non-controllinginterests£m Totalequity£m At 1 January 2026 1,349 3,498 10,209 1,321 16,377 (421) 15,956 Profit for the period 3,715 3,715 380 4,095 Other comprehensive income/(expense) for the period (55) 159 104 1 105 Total comprehensive income/(expense) for the period 3,660 159 3,819 381 4,200 Dividend distributions to non-controlling interests (354) (354) Derecognition of liabilities with non-controllinginterests 789 789 789 Contributions from non-controlling interests 187 187 1,399 1,586 Other distributions to non-controlling interests (1,399) (1,399) Dividends to shareholders (2,052) (2,052) (2,052) Realised after tax profit/(losses) on disposal orliquidation of equity investments 140 (140) – Share of associates and joint ventures realisedprofit/(loss) on disposal of equity investments 63 (63) – Shares issued 9 9 9 Purchase of treasury shares (634) (634) (634) Write-down of shares held by ESOP Trusts (171) 171 – Share-based incentive plans 267 267 267 Changes to non-controlling interests 2 2 Hedging gain/loss after taxation transferred to non-financial assets (8) (8) (8) At 30 September 2026 1,349 3,507 12,458 1,440 18,754 (392) 18,362 Sharecapital£m Sharepremium£m Retainedearnings£m Otherreserves£m Share-holder’sequity£m Non-controllinginterests£m Totalequity£m At 1 January 2025 1,348 3,473 7,796 1,054 13,671 (585) 13,086 Profit for the period 5,080 5,080 482 5,562 Other comprehensive income/(expense) for the period 371 87 458 (14) 444 Total comprehensive income/(expense) for the period 5,451 87 5,538 468 6,006 Dividend distributions to non-controlling interests (279) (279) Dividends to shareholders (1,918) (1,918) (1,918) Realised after tax profit/(losses) on disposal orliquidation of equity investments 26 (26) – Share of associates and joint ventures realisedprofit/(loss) on disposal of equity investments (1) 1 – Shares issued 1 13 14 14 Purchase of treasury shares(*) (1,425) (1,425) (1,425) Write-down of shares held by ESOP Trusts (181) 181 – Share-based incentive plans 268 268 268 At 30 September 2025 1,349 3,486 10,016 1,297 16,148 (396) 15,752 (*) Included shares committed to repurchase under irrevocable contracts and repurchases subject to settlement at the end of the period. Cash flow statement nine months ended 30 September 2026 9 months 2026£m 9 months 2025£m Profit after tax 4,095 5,562 Tax on profits 338 889 Share of after tax loss/(profit) of associates and joint ventures 9 (2) Net finance expense 459 383 Depreciation, amortisation, impairments and other adjusting items 3,527 2,720 (Increase)/decrease in working capital (1,521) (2,025) Contingent consideration paid (1,095) (989) Increase/(decrease) in other net liabilities (excluding contingent consideration paid) 1,566 (284) Cash generated from operations 7,378 6,254 Taxation paid (738) (791) Total net cash inflow/(outflow) from operating activities 6,640 5,463
Page 20
Cash flow from investing activities Purchase of property, plant and equipment (923) (775) Proceeds from sale of property, plant and equipment 33 11 Purchase of intangible assets (706) (1,185) Proceeds from sale of intangible assets 356 112 Purchase of equity investments (43) (52) Proceeds from sale of equity investments 219 138 Purchase of businesses, net of cash acquired (9,247) (1,655) Contingent consideration paid (96) (11) Disposal of businesses 247 (28) Interest received 100 117 (Increase)/decrease in liquid investments (20) 11 Dividends and distributions from joint ventures and associates 79 – Dividend and distributions from investments 38 17 Total net cash inflow/(outflow) from investing activities (9,963) (3,300) Cash flow from financing activities Issue of share capital 9 14 Repayment of long-term loans (1,466) (1,402) Issue of long-term notes 7,779 1,979 Net increase/(decrease) in short-term loans (246) 551 Increase in other short-term loans 11 112 Repayment of other short-term loans (106) (282) Repayment of lease liabilities (152) (166) Interest paid (431) (384) Dividends paid to shareholders (2,052) (1,918) Purchase of treasury shares (634) (1,125) Dividend distributions to non-controlling interests (354) (279) Other distributions to non-controlling interests (1,399) – Contributions from non-controlling interests 1,588 – Other financing items 246 71 Total net cash inflow/(outflow) from financing activities 2,793 (2,829) Increase/(decrease) in cash and bank overdrafts in the period (530) (666) Cash and bank overdrafts at beginning of the period 3,207 3,403 Adjustment on initial application of amendments to IFRS 9 on 1 January 2026(1) 43 – Cash and bank overdrafts at beginning of the period, as adjusted 3,250 3,403 Exchange adjustments (39) 22 Increase/(decrease) in cash and bank overdrafts in the period (530) (666) Cash and bank overdrafts at end of the period 2,681 2,759 Cash and bank overdrafts at end of period comprise: Cash and cash equivalents 2,934 3,296 Overdrafts (253) (537) 2,681 2,759 (1) For further details see page 31 Sales tables Specialty Medicines turnover – three months ended 30 September 2026 Total US Europe International £m AER%CER% £m AER% CER% £m AER% CER% £m AER% CER% HIV 2,116 9 10 1,524 13 14 399 5 6 193 (11) (11) Dolutegravir products 1,445 2 3 946 6 7 329 1 2 170 (14) (15) Dovato 754 8 9 443 12 13 221 8 9 90 (3) (6) Juluca 171 9 10 140 11 12 28 – – 3 – – Tivicay 319 (3) (2) 207 6 6 53 (9) (7) 59 (22) (20) Triumeq 201 (15) (14) 156 (11) (10) 27 (21) (21) 18 (31) (31) Long Acting Injectables 621 30 31 538 31 32 63 24 24 20 33 40 Apretude 143 19 21 136 17 18 2 – – 5 25 50 Cabenuva 478 34 35 402 36 38 61 20 20 15 36 36 Other 50 2 – 40 – – 7 75 50 3 (40) (40) Respiratory, Immunology& Inflammation 1,139 19 21 758 22 23 173 5 5 208 24 27 Benlysta 520 16 17 434 18 19 37 6 6 49 14 14 Exdensur 27 – – 14 – – 2 – – 11 – – Nucala 582 17 18 310 23 24 136 2 3 136 19 21 Other 10 25 37 – – – (2) 33 33 12 9 27 Oncology 622 22 23 392 12 13 154 26 26 76 90 93 Blenrep 50 – – 25 – – 15 – – 10 – – Jemperli 273 19 19 191 12 13 57 30 30 25 67 60 Jideytro 3 – – 3 – – – – – – – –
Page 21
Ojjaara/Omjjara 195 34 35 129 23 25 40 43 43 26 100 100 Zejula 104 (24) (23) 44 (40) (38) 44 (14) (12) 16 23 15 Other (3) (50) (50) – – – (2) >(100) >(100) (1) – – Specialty Medicines 3,877 14 15 2,674 15 17 726 9 9 477 12 13 Specialty Medicines turnover – nine months ended 30 September 2026 Total US Europe International £m AER%CER% £m AER% CER% £m AER% CER% £m AER% CER% HIV 6,018 9 10 4,203 12 14 1,205 6 4 610 (4) (5) Dolutegravir products 4,181 2 3 2,622 3 6 1,011 4 2 548 (6) (7) Dovato 2,169 13 14 1,218 13 16 673 13 11 278 11 10 Juluca 487 3 5 393 4 7 86 (1) (3) 8 (11) – Tivicay 948 (3) (2) 581 3 5 165 (5) (7) 202 (15) (16) Triumeq 577 (20) (19) 430 (17) (15) 87 (26) (27) 60 (30) (29) Long Acting Injectables 1,702 31 33 1,469 31 34 180 22 20 53 56 56 Apretude 403 30 33 387 27 31 4 – – 12 >100 >100 Cabenuva 1,299 31 33 1,082 32 36 176 20 18 41 46 46 Other 135 (6) (5) 112 2 5 14 8 (8) 9 (57) (52) Respiratory, Immunology& Inflammation 3,164 16 18 2,064 18 21 519 11 8 581 16 20 Benlysta 1,402 12 14 1,147 12 15 112 14 11 143 7 10 Exdensur 56 – – 33 – – 4 – – 19 – – Nucala 1,676 16 18 884 21 24 410 6 4 382 16 20 Other 30 29 42 – – – (7) 49 49 37 – 11 Oncology 1,703 21 22 1,087 11 14 428 29 26 188 88 94 Blenrep 109 >100 >100 55 – – 35 >100 >100 19 – – Jemperli 753 25 27 543 19 22 145 36 33 65 76 78 Jideytro 3 – – 3 – – – – – – – – Ojjaara/Omjjara 526 33 35 350 15 18 113 71 68 63 >100 >100 Zejula 319 (24) (23) 136 (37) (35) 141 (14) (15) 42 8 8 Other (7) 22 22 – – – (6) 25 12 (1) – >100 Specialty Medicines 10,885 13 14 7,354 13 16 2,152 11 9 1,379 11 13 Vaccines turnover – three months ended 30 September 2026 Total US Europe International £m AER%CER% £m AER% CER% £m AER% CER% £m AER% CER% Shingles 780 (6) (5) 290 13 14 289 (3) (1) 201 (27) (26) Shingrix 780 (6) (5) 290 13 14 289 (3) (1) 201 (27) (26) Meningitis 599 11 12 358 13 15 144 (6) (5) 97 37 34 Bexsero 378 3 4 178 10 12 142 (6) (5) 58 7 4 Menveo 189 13 14 150 1 2 2 – – 37 >100 >100 Penmenvy 30 >100 >100 30 >100 >100 – – – – – – Other 2 100 100 – – – – (100) – 2 – – RSV 195 (22) (24) 55 (61) (60) 103 37 36 37 3 (6) Arexvy 195 (22) (24) 55 (61) (60) 103 37 36 37 3 (6) Influenza 177 (18) (17) 125 (23) (21) 17 (6) (6) 35 – – Fluarix, FluLaval 177 (18) (17) 125 (23) (21) 17 (6) (6) 35 – – Other Paediatric &Adult Vaccines 832 (1) – 438 13 14 182 1 (1) 212 (21) (19) Boostrix 211 16 17 146 20 20 36 – 3 29 21 21 Hepatitis 188 3 3 105 4 6 48 (11) (13) 35 25 21 Infanrix, Pediarix 153 6 7 103 12 13 23 (15) (15) 27 4 8 Priorix, Priorix Tetra,Varilrix 83 (43) (42) 22 47 40 36 12 6 25 (75) (71) Rotarix 153 1 3 59 9 11 29 (12) (12) 65 – 3 Other 44 37 50 3 (40) 20 10 >100 >100 31 11 14 Vaccines 2,583 (4) (2) 1,266 – 2 735 1 2 582 (16) (15) Vaccines turnover – nine months ended 30 September 2026 Total US Europe International £m AER%CER% £m AER% CER% £m AER% CER% £m AER% CER% Shingles 2,694 6 6 924 6 9 1,184 25 22 586 (20) (17) Shingrix 2,694 6 6 924 6 9 1,184 25 22 586 (20) (17) Meningitis 1,396 10 11 619 6 9 473 5 3 304 27 28 Bexsero 972 8 8 315 2 4 466 6 4 191 28 30 Menveo 352 1 3 257 (4) (1) 6 – – 89 17 17 Penmenvy 47 >100 >100 47 >100 >100 – – – – – – Other 25 56 50 – – – 1 (50) (50) 24 71 64 RSV 452 14 12 138 (40) (38) 176 57 54 138 >100 >100 Arexvy 452 14 12 138 (40) (38) 176 57 54 138 >100 >100 Influenza 198 (11) (9) 129 (19) (17) 18 – – 51 11 13 Fluarix, FluLaval 198 (11) (9) 129 (19) (17) 18 – – 51 11 13
Page 22
Other Paediatric &Adult Vaccines 2,276 (6) (5) 1,050 2 5 559 8 5 667 (24) (23) Boostrix 551 9 11 359 15 18 112 2 – 80 (2) (4) Hepatitis 496 (2) (2) 246 (9) (6) 152 1 (1) 98 13 11 Infanrix, Pediarix 384 (7) (6) 228 (6) (3) 83 1 (1) 73 (20) (18) Priorix, Priorix Tetra,Varilrix 246 (25) (24) 54 12 15 103 14 11 89 (53) (51) Rotarix 419 (2) – 151 10 13 88 (4) (7) 180 (9) (7) Other 180 (27) (27) 12 (37) (37) 21 >100 >100 147 (37) (36) Vaccines 7,016 2 3 2,860 – 2 2,410 18 15 1,746 (11) (9) General Medicines turnover – three months ended 30 September 2026 Total US Europe International £m AER%CER% £m AER% CER% £m AER% CER% £m AER% CER% Respiratory 1,708 – 1 946 3 4 316 (7) (6) 446 – 1 Anoro Ellipta 138 1 1 49 (4) (2) 62 3 2 27 4 4 Flixotide/Flovent 73 (26) (24) 47 (28) (29) 11 (21) (21) 15 (21) (11) Relvar/Breo Ellipta 221 (14) (12) 76 (22) (22) 76 (13) (13) 69 (4) – Seretide/Advair 191 (4) (4) 66 8 10 34 (23) (20) 91 (3) (4) Trelegy Ellipta 787 7 8 572 7 8 88 5 5 127 9 11 Ventolin 181 16 17 108 40 40 26 (4) – 47 (10) (10) Other Respiratory 117 (3) (1) 28 (10) – 19 (17) (9) 70 6 2 Other General Medicines719 (5) (3) 45 (12) (12) 151 3 4 523 (7) (4) Blujepa 1 – – 1 – – – – – – – – Other General Medicines718 (5) (3) 44 (14) (14) 151 3 4 523 (7) (4) General Medicines 2,427 (1) – 991 2 3 467 (4) (3) 969 (4) (2) General Medicines turnover – nine months ended 30 September 2026 Total US Europe International £m AER%CER% £m AER% CER% £m AER% CER% £m AER% CER% Respiratory 4,981 (6) (4) 2,634 (9) (6) 1,012 (2) (4) 1,335 (2) – Anoro Ellipta 405 (1) (1) 137 (16) (13) 191 10 8 77 4 4 Flixotide/Flovent 291 (6) (4) 197 (2) – 41 (13) (15) 53 (13) (10) Relvar/Breo Ellipta 682 (13) (12) 228 (25) (23) 243 (9) (11) 211 (3) 1 Seretide/Advair 574 (7) (6) 187 5 8 121 (13) (14) 266 (11) (10) Trelegy Ellipta 2,208 (2) – 1,570 (5) (3) 265 7 5 373 9 12 Ventolin 455 (10) (9) 229 (14) (12) 80 (7) (8) 146 (6) (5) Other Respiratory 366 (11) (10) 86 (27) (24) 71 (10) (11) 209 (1) (2) Other General Medicines2,043 (9) (6) 128 (22) (21) 479 7 4 1,436 (11) (8) Blujepa 2 – – 2 – – – – – – – – Other General Medicines2,041 (9) (7) 126 (24) (22) 479 7 4 1,436 (11) (8) General Medicines 7,024 (7) (5) 2,762 (9) (7) 1,491 – (2) 2,771 (7) (4) Commercial Operations turnover Total US Europe International £m AER%CER% £m AER%CER% £m AER%CER% £m AER%CER% Three months ended 30September 2026 8,887 4 5 4,931 8 10 1,928 3 3 2,028 (4) (3) Nine months ended 30September 2026 24,925 4 5 12,976 5 7 6,053 11 8 5,896 (4) (2) Segment information Operating segments are reported based on the financial information provided to the Chief Executive Officer, who is the Chief Operating Decision Maker, as well as based on the responsibilities of the Executive Committee ("ExCom"). GSK reports results under two segments: Commercial Operations and Total R&D. The Group reviews its assessment of reportable segments on an ongoing basis. Adjusting items reconciling segment profit and operating profit comprise items not specifically allocated to segment profit. Details of adjusting items can be found on pages 14-19. Turnover by segment Q3 2026£m Q3 2025£m AER %CER % 9 months 2026£m 9 months 2025£m AER %CER % Commercial Operations (totalturnover) 8,887 8,547 4 5 24,925 24,049 4 5 Operating profit by segment
Page 23
Q3 2026£m Q3 2025£m AER %CER % 9 months 2026£m 9 months 2025£m AER %CER % Commercial Operations 4,892 4,514 8 10 13,559 12,540 8 10 Research and Development (1,787) (1,489) 20 21 (4,776) (4,309) 11 12 Segment profit 3,105 3,025 3 4 8,783 8,231 7 9 Corporate and other unallocated costs (29) (40) (257) (82) Core operating profit 3,076 2,985 3 5 8,526 8,149 5 7 Adjusting items (949) (392) (3,625) (1,317) Total operating profit 2,127 2,593 (18) (16) 4,901 6,832 (28) (25) Finance income 29 26 109 130 Finance costs (219) (167) (568) (513) Share of after tax profit/(loss) ofassociates and joint ventures (2) 4 (9) 2 Profit before taxation 1,935 2,456 (21) (19) 4,433 6,451 (31) (28) Commercial Operations Core operating profit growth in Q3 2026 and YTD 2026 primarily reflected higher turnover, favourable product and regional mix, ongoing productivity initiatives and supply chain optimisation, higher royalty income and favourable net legal settlements and expenses in Q1 2026, partly offset by increased investment in asset launches. Total R&D The R&D segment operating expense increased in Q3 2026 and YTD 2026 reflecting progression across the portfolio, primarily in Oncology. This included acceleration in work on ADCs Ris-Rez and Mo-Rez, and velzatinib and, following the Nuvalent acquisition, on Jideytro (zidesamtinib), approved by the FDA in the quarter and neladalkib. In Specialty Medicines, increased investment was driven by efimosfermin acquired in Q3 2025, depemokimab COPD indication and all indications of felcorekibart (the anti-TSLP monoclonal antibody). Growth was partly offset by lower spend on bepirovirsen which was filed in Q1 2026. Investment also increased on clinical trial programmes associated with mRNA seasonal flu vaccines. Legal matters The Group is involved in significant legal and administrative proceedings, principally product liability, intellectual property, tax, anti-trust, consumer fraud and governmental investigations, which are more fully described in the ‘Legal Proceedings’ note in the Annual Report 2025. At 30 September 2026, the Group’s aggregate provision for legal and other disputes (not including tax matters described on pages 6 and 7) was £202 million (31 December 2025: £210 million). The Group may become involved in significant legal proceedings in respect of which it is not possible to meaningfully assess whether the outcome will result in a probable outflow, or to quantify or reliably estimate the liability, if any, that could result from ultimate resolution of the proceedings. In these cases, the Group would provide appropriate disclosures about such cases, but no provision would be made. The ultimate liability for legal claims may vary from the amounts provided and is dependent upon the outcome of litigation proceedings, investigations and possible settlement negotiations. The Group’s position could change over time, and, therefore, there can be no assurance that any losses that result from the outcome of any legal proceedings will not exceed by a material amount the amount of the provisions reported in the Group’s financial accounts. Significant legal developments since the date of the Q2 2026 results: Commercial and corporate Tesaro, Inc. v. AnaptysBio A post-trial hearing was held before the Delaware Chancery Court on 20 October 2026. A decision is expected in Q4 2026 or Q1 2027. Intellectual Property Trelegy Ellipta The U.S. District Court for the Southern District of Florida has consolidated the two Trelegy patent infringement cases which GSK filed against Transpire. Both cases have been set for trial on 22 February 2028. Returns to shareholders Quarterly dividends The Board has declared a third interim dividend for Q3 2026 of 17p per share (Q3 2025: 16p per share).
Page 24
Dividends remain an essential component of total shareholder return and GSK recognises the importance of dividends to shareholders. On 23 June 2021, at the GSK Investor Update, GSK set out that from 2022 a progressive dividend policy will be implemented guided by a 40 to 60 per cent pay-out ratio through the investment cycle. Consistent with this, GSK has declared a dividend of 17p per share for Q3 2026. The expected dividend for 2026 is 70p per share. In setting its dividend policy, GSK considers the capital allocation priorities of the Group and its investment strategy for growth alongside the sustainability of the dividend. Dividend dates Ex-dividend date(Ordinary shares) Ex-dividend date(ADRs) Record date Payment date Q3 2026 12 November 2026 13 November 2026 13 November 2026 7 January 2027 Ordinary shareholders may participate in the dividend reinvestment plan (DRIP). The last date for DRIP elections is 14 December 2026. The equivalent interim dividend receivable by ADR holders will be calculated based on the exchange rate on 5 January 2027. An annual fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by the Depositary. Paid/Payable Pence pershare £m 2026 First interim 9 July 2026 17 682 Second interim 8 October 2026 17 682 Third interim 7 January 2027 17 682 2025 First interim 10 July 2025 16 650 Second interim 9 October 2025 16 646 Third interim 8 January 2026 16 643 Fourth interim 9 April 2026 18 727 66 2,666 Share capital in issue At 30 September 2026, 4,009 million shares (Q3 2025: 4,026 million) were in free issue (excluding Treasury shares and shares held by the ESOP Trusts). The Company issued a small number of shares in the quarter (Q3 2025: minimal number) under employee share schemes for net proceeds of £0.4 million (Q3 2025: £0.4 million). On 5 February 2025, GSK announced a £2 billion share buyback programme to be completed over an 18-month period. This share buyback programme was completed on 26 June 2026, with a total of 124 million shares repurchased and being held as Treasury shares, at a cost of £2,011 million including transaction costs of £11 million. At 30 September 2026, the Company held 271 million Treasury shares at a cost of £4,580 million, of which 147 million shares at a cost of £2,571 million were repurchased as part of previous share buyback programmes, which has been deducted from retained earnings. At 30 September 2026, the ESOP Trusts held 36.5 million shares, of which 35.9 million were held for the future exercise of share options and share awards and 0.6 million were held for the Executive Supplemental Savings plan. The carrying amount of £114 million has been deducted from other reserves. The market value of these shares was £670 million. Weighted average number of shares The numbers of shares used in calculating basic and diluted earnings per share are reconciled below: Q3 2026millions Q3 2025millions 9 months 2026millions 9 months 2025millions Weighted average number of shares – basic 4,009 4,034 4,015 4,062 Dilutive effect of share options and share awards 64 68 64 67 Weighted average number of shares – diluted 4,073 4,102 4,079 4,129 Additional information Accounting policies and basis of preparation This unaudited Results Announcement contains condensed financial information for the three and nine months ended 30 September 2026 and should be read in conjunction with the Annual Report 2025, which was prepared in accordance with UK-adopted international accounting standards in conformity with the requirements of the Companies Act 2006 and the IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB). This Results Announcement has been prepared applying consistent accounting policies to those applied by the Group in the Annual Report 2025, except for the adoption of the amended IFRS Accounting Standard as set out below. Other minor amendments to IFRS Accounting Standards which were effective from 1 January 2026 did not have a material impact on the Group accounting policies or Group financial statements.
Page 25
•Amendments to the Classification and Measurement of Financial Instruments - Amendments to IFRS 9 and IFRS 7: the amendments to IFRS 9 ‘Financial Instruments’, clarify the timing of recognition and derecognition of a financial asset or financial liability, with a permitted exception relating to a financial liability paid through an electronic payment system which may be derecognised prior to its settlement date where specific conditions are met. GSK has adopted these new requirements for the reporting period beginning on 1 January 2026 and elected to derecognise financial liabilities paid through an electronic payment system when the required conditions have been met. The impact on the Group’s financial statements on transition as at 1 January 2026 is disclosed below and primarily relates to cheques which were issued but had not yet cleared from the bank account before the transition date. As permitted under the transition requirements, the Group has elected not to restate the comparative information to reflect the application of these amendments. As at1 January 2026£m Adjustment on initial application ofamendments toIFRS 9 and IFRS 7£m As at1 January 2026as adjusted£m Trade and other payables (15,381) (43) (15,424) Bank overdrafts (within short-termborrowings) (190) 29 (161) Cash and cash equivalents 3,397 14 3,411 The Group has not identified any changes to its key sources of accounting judgements or estimations of uncertainty compared with those disclosed in the Annual Report 2025. This Results Announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The full Group accounts for 2025 were published in the Annual Report 2025, which has been delivered to the Registrar of Companies and on which the report of the independent auditor was unqualified and did not contain a statement under section 498 of the Companies Act 2006. Contingent liabilities There were contingent liabilities at 30 September 2026 in respect of arrangements entered into as part of the ordinary course of the Group’s business. No material losses are expected to arise from such contingent liabilities. Provision is made for the outcome of legal and tax disputes where it is both probable that the Group will suffer an outflow of funds and it is possible to make a reliable estimate of that outflow. Descriptions of the significant legal disputes to which the Group is a party are set out on page 29, and pages 269 to 272 of the 2025 Annual Report. Net assets The book value of net assets increased by £2,406 million from £15,956 million at 31 December 2025 to £18,362 million at 30 September 2026. This primarily reflected contribution from Total comprehensive income for the period and the special dividend from the ViiV Healthcare shareholding restructure, partly offset by dividends paid to shareholders, shares repurchased under the share buyback programme and associated transaction costs. At 30 September 2026, the net surplus on the Group’s pension plans was £567 million compared with a net surplus of £229 million at 31 December 2025. This movement was primarily driven by an increase in the UK and US discount rate from 5.5% to 6.6% and 5.1% to 6.2% respectively, which was partially offset by an increase to the UK inflation rate from 2.7% to 3.1%. The estimated present value of the potential redemption amount of the Pfizer put option related to ViiV Healthcare, recorded in Other payables in Current liabilities, was £nil (31 December 2025: £822 million). The put option liability was fully derecognised at 31 March 2026 as Pfizer has exited its shareholding in ViiV Healthcare. Contingent consideration amounted to £6,629 million at 30 September 2026 (31 December 2025: £6,733 million) as follows: Group30 September2026£m Group31 December2025£m Contingent consideration estimated present value of amounts payable relating to: Former Shionogi-ViiV Healthcare joint venture 5,301 5,433 Former Novartis Vaccines business acquisition 632 651 BP Asset IX, Inc. acquisition 236 231 Affinivax acquisition 234 219 Others 226 199 Contingent consideration liability at end of the period 6,629 6,733 Of the contingent consideration payable to Shionogi at 30 September 2026, £1,243 million (31 December 2025: £1,194 million) is expected to be paid within one year. Movements in contingent consideration are as follows: ViiV Healthcare Group
Page 26
9 months 2026£m 9 months 2025£m 9 months 2026£m 9 months 2025£m Contingent consideration at beginning of the period 5,433 6,061 6,733 7,280 Additions – – – 280 Remeasurement through income statement and othermovements 920 161 1,087 223 Cash payments: operating cash flows (1,052) (956) (1,095) (989) Cash payments: investing activities – – (96) (11) Contingent consideration at end of the period 5,301 5,266 6,629 6,783 Business acquisitions On 3 March 2026, GSK acquired 100% of the outstanding equity of RAPT Therapeutics, Inc. ("RAPT") a California-based clinical stage biopharmaceutical company for US$2.3 billion (£1.7 billion), including transaction fees. Net of cash acquired, GSK's upfront investment was approximately US$1.9 billion (£1.4 billion). The transaction gives GSK the global rights to the ozureprubart programme, excluding mainland China, Macau, Taiwan and Hong Kong. On 14 April 2026, GSK acquired 100% of 35Pharma, Inc. ("35Pharma") a Canada-based, private, clinical-stage biopharmaceutical company for total consideration of US$1.0 billion (£756 million), comprising US$988 million (£731 million) upfront and US$34 million (£25 million) of deferred consideration. Net of cash acquired, GSK's net investment was US$945 million (£700 million). The acquisition provides global rights to HS235, a potential best-in-class activin signalling inhibitor being developed for the treatment of pulmonary hypertension. On 15 July 2026, GSK completed the acquisition of 100% of Nuvalent, Inc. ("Nuvalent") a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies. Under the terms of the agreement, GSK paid Nuvalent shareholders US$124 per share at closing for an aggregate equity value of US$10.8 billion (£8.0 billion), including transaction fees. Net of cash acquired, GSK's upfront investment was approximately US$9.6 billion (£7.1 billion). The acquisition includes three products in lung cancer in a single transaction, including zidesamtinib (NVL-520) and neladalkib (NVL-655) which are two potential best-in-class, next-generation, highly selective ROS1 and ALK inhibitors for the treatment of NSCLC. During the period to 30 September 2026, no sales arising from RAPT or 35Pharma were included in Group turnover and no revenue is expected until regulatory approval is received on the acquired assets. GSK continues to support the ongoing development of the acquired assets and consequently these assets will be loss making until regulatory approval on these assets is received. The impact on Group Total profit after taxation for the period ended 30 September 2026 from the RAPT and 35Pharma acquisitions was immaterial. Following US FDA approval of Jideytro (zidesamtinib) on 22 July 2026, Nuvalent began commercial sales. Revenue was not material to Group turnover. Nuvalent contributed a Total operating loss of US$148 million (£110 million) to the Group Total operating profit for the period since 15 July 2026. The acquired assets that remain in development will be integrated into the Group’s existing R&D activities, after which it will be impracticable to quantify these development costs or the impact on Group Total profit after taxation. The initial acquisition accounting for Nuvalent was reflected in the third quarter of 2026 on a provisional basis. The accounting for RAPT and 35Pharma also remains provisional and subject to change. Goodwill of £1.2 billion (£211 million for RAPT, £106 million for 35Pharma and £852 million for Nuvalent) has been recognised. The goodwill represents specific synergies available to GSK from the business combination. The goodwill has been allocated to the Group’s Commercial Operations and R&D segments. None of the goodwill is expected to be deductible for tax purposes. The provisional fair values of the net assets acquired, including goodwill, are as follows: RAPT 35Pharma Nuvalent Total £m £m £m £m Net assets acquired: Intangible assets 1,457 700 8,077 10,234 Property, plant & equipment 1 – – 1 Other non-current assets – – 17 17 Inventory – – 24 24 Trade and other receivables – – 10 10 Cash and cash equivalents 281 56 897 1,234 Other net liabilities (13) (1) (86) (100) Other long-term liabilities – – (446) (446) Deferred tax liabilities (252) (105) (1,305) (1,662) 1,474 650 7,188 9,312 Goodwill 211 106 852 1,169 Total consideration 1,685 756 8,040 10,481 The total consideration of £10.5 billion (£1.7 billion for RAPT, £0.8 billion for 35Pharma and £8.0 billion for Nuvalent), was fully paid as at 30 September 2026, including the £20 million of 35Pharma deferred consideration which was outstanding at Q2 2026.
Page 27
Net debt information Reconciliation of cash flow to movements in net debt 9 months 2026£m 9 months 2025£m Total Net debt at beginning of the period (14,453) (13,095) Adjustment on initial application of amendments to IFRS 9 on 1 January 2026(1) 43 – Total Net debt at beginning of the period, as adjusted (14,410) (13,095) Increase/(decrease) in cash and bank overdrafts (530) (666) Increase/(decrease) in liquid investments 20 (11) Repayment of long-term loans 1,466 1,402 Issue of long-term notes (7,779) (1,979) Net decrease/(increase) in short-term loans 246 (551) Increase in other short-term loans (11) (112) Repayment of other short-term loans 106 282 Repayment of lease liabilities 152 166 Disposal of lease liabilities related to disposal of subsidiary 136 – Net debt of subsidiary undertakings acquired (2) (1) Exchange adjustments (85) 241 Other non-cash movements (48) (120) Decrease/(increase) in Net debt (6,329) (1,349) Total Net debt at end of the period (20,739) (14,444) (1) For further details see page 31 Net debt analysis 30 September 2026£m 31 December 2025£m Liquid investments 28 9 Cash and cash equivalents 2,934 3,397 Short-term borrowings (2,001) (3,012) Long-term borrowings (21,700) (14,708) Liabilities relating to assets held for sale – (139) Total Net debt at the end of the period (20,739) (14,453) Free cash flow reconciliation Q3 2026£m Q3 2025£m 9 months 2026£m 9 months 2025£m Net cash inflow/(outflow) from operating activities 2,809 2,222 6,640 5,463 Purchase of property, plant and equipment (374) (311) (923) (775) Proceeds from sale of property, plant and equipment 3 5 33 11 Purchase of intangible assets (159) (568) (706) (1,185) Proceeds from disposals of intangible assets 1 36 356 112 Net finance costs (66) (34) (331) (267) Dividends and distributions from associates and joint ventures 54 – 79 – Contingent consideration paid (reported in investing activities) (88) (5) (96) (11) Dividend distributions to non-controlling interests (102) (99) (354) (279) Other distributions to non-controlling interests – – (1,399) – Contributions from non-controlling interests – – 1,588 – Free cash inflow/(outflow) 2,078 1,246 4,887 3,069 Related party transactions There were no material related party transactions entered into and there have been no material changes to the related party transactions disclosed on page 241 of the 2025 Annual Report. R&D Commentary Pipeline Overview Medicines and vaccines in phase IIIdevelopment (including major lifecycleinnovation or under regulatory review) 21 Respiratory, Immunology & Inflammation (5) • Benlysta (anti-B lymphocyte stimulator (BlyS) mAb) systemic sclerosis-associated interstitial lung disease (SSc-ILD), connective tissue disease-associated interstitial lung disease [MR1.1] (CTD-ILD) • Exdensur (ultra long-acting anti-IL5 biologic), eosinophilic granulomatosis with polyangiitis (EGPA), hyper-eosinophilic syndrome(HES), chronic obstructive pulmonary disease (COPD)
Page 28
• efimosfermin (FGF21 analog) metabolic dysfunction-associatedsteatohepatitis (MASH) • felcorekibart (TSLP) asthma, chronic rhinosinusitis with nasal polyps,COPD • Ventolin (salbutamol, Beta 2 adrenergic receptor agonist) asthma Oncology (8) • Blenrep (anti-BCMA ADC) 1L multiple myeloma • Jemperli (anti-PD-1) 1L endometrial cancer, colon cancer, rectal cancer (ph II registrational), head and neck cancer • Jideytro (ROS-1 inhibitor) non-small cell lung cancer • Zejula (PARP inhibitor) glioblastoma • Mo-Rez (B7-H4 ADC) 2L+ advanced endometrial cancer, platinumresistant ovarian cancer, platinum sensitive ovarian cancer, and 1Lmaintenance ovarian and endometrial cancers • neladalkib (ALK inhibitor) non-small cell lung cancer • Ris-Rez (B7-H3 ADC) 2L extensive-stage small cell lung cancer, late-line metastatic castration-resistant prostate cancer • velzatinib (KIT inhibitor) gastro-intestinal stromal tumours HIV (1) • New intramuscular formulation of cabotegravir + rilpivirine (3x a yeartreatment) Infectious Diseases (7) • Arexvy (RSV vaccine) RSV, adults 18 years of age and above • bepirovirsen (HBV ASO) chronic hepatitis B • Bexsero (meningococcal B vaccine) infants (US) • GSK'116 (varicella vaccine) varicella new seed, individuals 12 months ofage and older • GSK'371 (MMRV vaccine) MMRV new seed • Shingrix (recombinant protein, adjuvanted vaccine) MACE • mRNA seasonal flu (double target flu HA-NA vaccine candidate) Total medicines and vaccines in all phasesof clinical development 62 Total projects in clinical development(inclusive of all phases and indications) 97 Therapy area updates The following provides updates on key medicines and vaccines by therapy area that will help drive growth for GSK to meet its future outlooks. Respiratory, Immunology & Inflammation efimosfermin (FGF21 analog) Efimosfermin (GSK6519754) is an investigational, once-monthly subcutaneous injection of a long-acting variant of FGF21, designed to regulate key metabolic pathways to decrease liver fat, ameliorate liver inflammation, and reverse liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH). Multiple phase III trials are ongoing for efimosfermin including both moderate and advanced fibrosis (F2 to F3) and compensated cirrhosis (F4) caused by MASH. In August, GSK also started the ALLSTAR phase II trial investigating efimosfermin for alcohol-related liver disease (ALD). Efimosfermin has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) and Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for the treatment of MASH. In September, China’s Center for Drug Evaluation (CDE) granted an additional Breakthrough Therapy Designation for F4 MASH, building on earlier designations in F2-F3 MASH. Breakthrough Designation is designed to expedite the development and review of medicines for serious conditions, where preliminary clinical evidence indicates potential for substantial improvement over available therapy. PRIME designation provides scientific and regulatory support for medicines that have the potential to address significant unmet medical need. Key trials for efimosfermin: Trial name (population)Phase Design Timeline Status ZENITH-1 (metabolicdysfunction-associatedsteatohepatitis) NCT07221227 III A phase III, randomised, double-blind, placebo-controlled, 3-armstudy to investigate the safety and efficacy of efimosfermin alfa inparticipants with biopsy-confirmed F2- or F3-stage metabolicdysfunction-associated steatohepatitis (MASH) Trial start:Q4 2025 Recruiting ZENITH-2 (metabolicdysfunction-associatedsteatohepatitis) NCT07221188 III A phase III, randomised, double-blind, placebo-controlled, 3-armstudy to investigate the safety and tolerability of efimosfermin alfa inparticipants with known or suspected F2- or F3-stage metabolicdysfunction-associated steatohepatitis (MASH) Trial start:Q4 2025 Recruiting NEBULA-1 (metabolicdysfunction-associatedsteatohepatitis)NCT07701993 III A phase III, double-blind, 2-arm study to investigate the safety andefficacy of efimosfermin alfa injection compared with placebo inadult participants with compensated cirrhosis (stage F4 fibrosis) dueto metabolic dysfunction-associated steatohepatitis (MASH) Trial start:Q3 2026 Recruiting
Page 29
NEBULA-2 (metabolicdysfunction-associatedsteatohepatitis)NCT07704892 III A phase III, two-part, double-blind, randomised, placebo-controlledstudy to investigate the safety and efficacy of efimosfermin alfainjection in adult participants with biopsy-confirmed compensatedcirrhosis (stage F4 fibrosis) due to metabolic dysfunction-associatedsteatohepatitis (MASH) Trial start:Q3 2026 Recruiting Exdensur (depemokimab; ultra-long-acting anti-IL5) Exdensur (depemokimab) is the first and only ultra-long-acting biologic to address severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). It is engineered to have an extended half-life and high binding affinity and potency for IL-5, enabling twice-yearly dosing. Exdensur is approved in over 40 countries for the treatment of severe asthma and CRSwNP, including EU, China, Japan, UK, Canada and Brazil, and for the treatment of severe asthma in the US. Depemokimab is currently being evaluated in phase III trials for the treatment of other diseases with underlying type 2 inflammation, including OCEAN for eosinophilic granulomatosis with polyangiitis (EGPA) and DESTINY for hypereosinophilic syndrome (HES). GSK has also initiated the ENDURA-1, ENDURA-2 and VIGILANT phase III trials assessing the efficacy and safety of depemokimab as an add-on therapy in patients with uncontrolled moderate to severe COPD with type 2 inflammation. At the 2026 European Respiratory Society (ERS) Congress, GSK presented data reinforcing depemokimab's differentiated profile, including sustained efficacy over two years in patients with severe asthma and consistent outcomes across key patient subgroups. Results from a patient preference study were also presented showing patient preference for less frequent dosing and identifying dosing frequency as a key reason for non-adherence. Key phase III trials for depemokimab: Trial name (population)Phase Design Timeline Status OCEAN (EGPA) NCT05263934 III A 52-week, randomised, double-blind, double-dummy, parallel-group, multicentre, non-inferioritystudy to investigate the efficacy and safety ofdepemokimab compared with mepolizumab in adultswith relapsing or refractory eosinophilicgranulomatosis with polyangiitis (EGPA) receivingstandard of care therapy Trial start:Q3 2022 Active, notrecruiting DESTINY (HES) NCT05334368 III A 52-week, randomised, placebo-controlled, double-blind, parallel group, multicentre trial ofdepemokimab in adults with uncontrolled HESreceiving standard of care therapy Trial start:Q3 2022 Active, notrecruiting ENDURA-1 (COPD)NCT06959095 III A randomised, double-blind, placebo-controlled,parallel-group, multicentre study of the efficacy andsafety of depemokimab in adult participants withCOPD with type 2 inflammation Trial start:Q2 2025 Recruiting ENDURA-2 (COPD)NCT06961214 III A randomised, double-blind, placebo-controlled,parallel-group, multicentre study of the efficacy andsafety of depemokimab in adult participants withCOPD with type 2 inflammation Trial start:Q2 2025 Recruiting VIGILANT (COPD)NCT07177339 III A randomised, double-blind, parallel group, placebo-controlled study of the efficacy and safety of earlydepemokimab initiation as add-on treatment in COPDpatients with type 2 inflammation Trial start:Q4 2025 Recruiting felcorekibart (GSK5784283; anti-TSLP) Felcorekibart (GSK5784283) is an investigational ultra-long-acting monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a key driver of inflammation across multiple respiratory diseases. In 2026, GSK initiated a broad global phase III development programme for felcorekibart across multiple respiratory diseases. The PERSIST programme comprises six Phase III trials, with two studies each in uncontrolled asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). These studies are evaluating the efficacy and safety of felcorekibart as an add-on treatment in patients with inadequately controlled disease. Trial name(population) Phase Design Timeline Status PERSISTASTHMA-1NCT07780643 III A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of felcorekibart(GSK5784283) as an add-on therapy in adults and adolescents withuncontrolled asthma Trial start:Q3 2026 Recruiting PERSISTASTHMA-2NCT07782996 III A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of felcorekibart(GSK5784283) as an add-on therapy in adults and adolescents withuncontrolled asthma Trial start:Q3 2026 Recruiting PERSISTCRSwNP-1NCT07782970 III A randomised, double-blind, parallel-group Phase III study to assess theefficacy and safety of felcorekibart (GSK5784283) in participants withchronic rhinosinusitis with nasal polyps (CRSwNP) Trial start:Q3 2026 Recruiting PERSISTCRSwNP-2NCT07782957 III A randomised, double-blind, parallel-group Phase III study to assess theefficacy and safety of felcorekibart (GSK5784283) compared withplacebo in participants with chronic rhinosinusitis with nasal polyps(CRSwNP) Trial start:Q3 2026 Recruiting
Page 30
PERSIST COPD-1NCT07780669 III A randomised, double-blind, placebo-controlled, parallel-group,multicentre study of the efficacy and safety of felcorekibart(GSK5784283) in participants 40 to 80 years of age with moderate tovery severe COPD Trial start:Q3 2026 Recruiting PERSIST COPD-2NCT07780656 III A randomised, double-blind, placebo-controlled, parallel-group,multicentre study of the efficacy and safety of felcorekibart(GSK5784283) in participants 40 to 80 years of age with moderate tovery severe COPD Trial start:Q3 2026 Recruiting Oncology Blenrep (belantamab mafodotin) GSK is continuing the DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical development programme to explore the full potential of belantamab mafodotin, including in earlier lines of treatment. This includes DREAMM-10, a phase III clinical trial in newly diagnosed transplant-ineligible patients, who represent over 70% of patients starting multiple myeloma therapy. Key phase III trials for Blenrep: Trial name (population)Phase Design Timeline Status DREAMM-7 (2L+multiple myeloma; MM) NCT04246047 III A multicentre, open-label, randomised trial to evaluatethe efficacy and safety of the combination ofbelantamab mafodotin, bortezomib, anddexamethasone (B-Vd) compared with thecombination of daratumumab, bortezomib anddexamethasone (D-Vd) in participants withrelapsed/refractory multiple myeloma Trial start:Q2 2020 Primary datareported:Q4 2023 Active, notrecruiting;primary endpointmet DREAMM-8 (2L+ MM) NCT04484623 III A multicentre, open-label, randomised trial to evaluatethe efficacy and safety of belantamab mafodotin incombination with pomalidomide and dexamethasone(B-Pd) versus pomalidomide plus bortezomib anddexamethasone (P-Vd) in participants withrelapsed/refractory multiple myeloma Trial start:Q4 2020 Primary datareported:Q1 2024 Active, notrecruiting, primaryendpoint met DREAMM-10 (1L MM)NCT06679101 III A multicentre, open-label, randomised trial to evaluatethe efficacy and safety of belantamab mafodotin,lenalidomide and dexamethasone (B-Rd) versusdaratumumab, lenalidomide, and dexamethasone (D-Rd) in participants with newly diagnosed multiplemyeloma who are ineligible for autologous stem celltransplantation Trial start:Q4 2024 Recruiting Jemperli (dostarlimab) On 19 October, the US FDA approved Jemperli as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H) / mismatch repair deficient (dMMR) locally advanced rectal cancer. Approval was supported by the phase II AZUR-1 trial, which met its primary objective and demonstrated a clinically significant proportion of participants achieved sustained clinical complete responses at 12 months with data continuing to mature. The approval provides a new treatment approach that may help eligible patients avoid chemotherapy, radiation and surgery. Detailed interim findings from the AZUR-1 trial were presented in a late-breaking oral session at the 2026 ESMO Congress in October. Jemperli plays an important role in GSK’s immuno-oncology-based research and development programme. It is the only approved immuno-oncology-based plus carboplatin-paclitaxel (CP) treatment regimen to demonstrate a statistically significant and clinically meaningful overall survival benefit vs. CP alone for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer irrespective of biomarker status. Ongoing pivotal trials include those in the AZUR programme (colon / rectal cancers), JADE (head and neck cancer), and DOMENICA (supported-collaborative study with ARCAGY-GINECO in endometrial cancer). Key trials for Jemperli: Trial name (population)Phase Design Timeline Status RUBY (1L stage III or IVendometrial cancer) NCT03981796 III A randomised, double-blind, multicentre trial ofdostarlimab plus carboplatin-paclitaxel with andwithout niraparib maintenance versus placebo pluscarboplatin-paclitaxel in patients with recurrent orprimary advanced endometrial cancer Trial start:Q3 2019 Part 1 datareported:Q4 2022 Part 2 datareported:Q4 2023 Active, notrecruiting;primary endpointsmet GARNET (advancedsolid tumours) NCT02715284 I/II A multicentre, open-label, first-in-human trialevaluating dostarlimab in participants with advancedsolid tumours who have limited available treatmentoptions Trial start:Q1 2016 Primary datareported:Q1 2019 Active, notrecruiting AZUR-1 (stage II/IIIrectal cancer) NCT05723562 II A single-arm, open-label trial with dostarlimabmonotherapy in participants with untreated stage II/IIIdMMR/MSI-H locally advanced rectal cancer Trial start:Q1 2023Data reported:Q3 2026 Active, notrecruiting
Page 31
AZUR-2 (untreatedperioperative T4N0 orstage III colon cancer)NCT05855200 III An open-label, randomised trial of perioperativedostarlimab monotherapy versus standard of care inparticipants with untreated T4N0 or stage III MSI-H/dMMR resectable colon cancer Trial start:Q3 2023 Active, notrecruiting JADE (locally advancedunresected head and neckcancer)NCT06256588 III A randomised, double-blind, study to evaluatedostarlimab versus placebo as sequential therapy afterchemoradiation in participants with locally advancedunresected head and neck squamous cell carcinoma Trial start:Q1 2024 Active, notrecruiting SAPPHIRE (endometrialcancer)NCT07860450 I/III An open-label, multicenter, two-part study: a phase 1bdose selection followed by a randomised phase 3 toevaluate the pharmacokinetics, efficacy, and safety ofsubcutaneous dostarlimab plus carboplatin-paclitaxelversus intravenous dostarlimab plus carboplatin-paclitaxel in participants with primary advanced orrecurrent endometrial cancer Trial start:Q4 2026 Not active, notrecruiting DOMENICA* (relapsedor advanced dMMRendometrial cancer)NCT05201547*supported-collaborativestudy with ARCAGY-GINECO III A randomised, multicentre study to evaluate theefficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with dMMR relapsed oradvanced endometrial cancer Trial start:Q2 2022 Active, notrecruiting Risvutatug rezetecan (Ris-Rez) Ris-Rez is a novel investigational antibody-drug conjugate targeting the B7-H3 protein, which is highly expressed in more than 10 solid tumour types, supporting the ambition of GSK’s EMBOLD global trial programme to develop Ris-Rez across more than 40 indications by 2040. In September 2026, GSK started its second global phase III trial for Ris-Rez, EMBOLD Prostate-302, studying Ris-Rez in patients with metastatic castration-resistant prostate cancer. Also in September, GSK's licensor Hansoh Pharma presented pivotal phase III data at the World Conference on Lung Cancer showing Ris-Rez significantly reduced the risk of death versus topotecan in patients with relapsed small cell lung cancer (SCLC) in China. The results provide further momentum for GSK’s global development of Ris-Rez across later-line and earlier treatment settings for SCLC. At the 2026 ESMO Congress in October, GSK presented the first global data for Ris-Rez in patients with relapsed extensive- stage SCLC. Results from the phase Ib dose-optimisation portion of the EMBOLD PanTumour-101 trial showed positive anti- tumour activity and a manageable safety profile. These results supported selection of the 8 mg/kg dose currently being evaluated in GSK’s global phase III EMBOLD SCLC-301 trial in the same tumour type. Also at ESMO, Hansoh Pharma presented positive data from its second phase III trial of Ris-Rez this year, ARTEMIS-011 in patients with relapsed osteosarcoma in China. The results showed Ris-Rez significantly reduced the risk of disease progression or death compared with chemotherapy, after a median follow-up of 7.1 months. Safety findings were consistent with prior findings in this tumour type. The results will help inform GSK's global development programme, including an ongoing EMBOLD Sarcoma 202 phase II trial in advanced osteosarcoma and soft tissue sarcoma. Key phase III trials for Ris-Rez: Trial name (population)Phase Design Timeline Status EMBOLD-SCLC-301NCT07099898 III A multicenter, randomised, open-label study ofrisvutatug rezetecan compared with topotecan inparticipants with relapsed small cell lung cancer Trial start:Q3 2025 Recruiting EMBOLD Prostate-302(prostate cancer)NCT07802704 III A multicenter, randomised, open-label study ofrisvutatug rezetecan compared with best supportivestandard of care, with or without androgen receptorpathway inhibitors, in participants with metastaticcastration-resistant prostate cancer Trial start:Q3 2026 Recruiting Mocertatug rezetecan (Mo‐Rez) GSK is advancing Mo‐Rez, a B7‐H4–targeting investigational antibody‐drug conjugate, through the global BEHOLD development programme across multiple gynaecological cancer indications, where significant unmet need remains. B7-H4 is an immune checkpoint that is widely expressed in ovarian and endometrial cancers, and is low in normal tissues, making it a promising target for clinical development. Five phase III pivotal trials for Mo-Rez have been initiated and are actively recruiting patients: BEHOLD‐Ovarian01 in platinum‐resistant ovarian cancer (PROC), BEHOLD‐Endometrial01 in advanced or recurrent endometrial cancer, BEHOLD- Ovarian02 in platinum sensitive ovarian cancer, BEHOLD-Ovarian03 in first‐line maintenance ovarian cancer without homologous recombination deficiency and BEHOLD‐Endometrial02 in first line maintenance mismatch repair–proficient endometrial cancer. In October 2026, GSK presented the latest safety positive data for Mo-Rez from the global phase I BEHOLD-1 trial at ESMO demonstrating clinically meaningful and durable responses at >13 months follow up, alongside a manageable safety for patients with PROC. The response to Mo-Rez observed across a range of B7-H4 expression levels reinforces its broad potential in gynaecologic cancers and further validates the relevance of targeting B7-H4. Key phase III trials for Mo-Rez:
Page 32
Trial name (population)Phase Design Timeline Status BEHOLD-Ovarian01GOG-3132 / ENGOT-o98/ APGOT-OV21NCT07286266 III A randomised, Open-label, Multicenter, Phase IIIStudy to Investigate mocertatug rezetecan ComparedWith Chemotherapy in Participants With Platinum-resistant Ovarian Cancer Trial start:Q2 2026 Recruiting BEHOLD-Endometrial01GOG-3131 / ENGOT-en34 / APGOT-EN4NCT07286331 III A randomised, Open-label, Multicenter, Phase IIIStudy to Investigate mocertatug rezetecan ComparedWith Chemotherapy in Participants With RecurrentEndometrial Cancer Trial start:Q2 2026 Recruiting BEHOLD-Ovarian02 /GOG-3136 / ENGOT-ov99 / APGOT-OV19NCT07684612 III A randomised, Open-Label, Multicenter, Phase 3Study to Investigate Mocertatug Rezetecan WithBevacizumab Compared With Platinum Doublet WithBevacizumab in Participants With Platinum-SensitiveOvarian Cancer Trial start:Q3 2026 Recruiting Trial name (population)PhaseDesign TimelineStatus BEHOLD-Ovarian03 /GOG-3135 / ENGOT-ov105 / APGOT-OV20NCT07694427 III A randomised, Open-label, Multicenter, Phase 3 Study to InvestigateMocertatug Rezetecan With or Without Bevacizumab in Comparison toActive Observation With or Without Bevacizumab as MaintenanceTreatment in Participants With Newly Diagnosed FIGO Stage III/IV Non-Homologous Recombination Deficient Ovarian Cancer Trialstart:Q4 2026 Recruiting BEHOLD-Endometrial02 /ENGOT-en33 / GOG-3130 / APGOT-EN5NCT07684599 III A randomised, Open-label, Multicenter, Phase 3 Study to InvestigateMocertatug Rezetecan in Combination With Immune CheckpointInhibition for Maintenance Treatment of Participants With MismatchRepair Proficient (MMRp) Endometrial Cancer Trialstart:Q3 2026 Recruiting Jideytro (zidesamtinib) Jideytro (zidesamtinib) is a ROS1 tyrosine kinase inhibitor (TKI) approved by the US FDA for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor. The FDA approval is based on results from the ARROS-1 (NCT05118789) global phase I/II trial evaluating zidesamtinib in patients with advanced ROS1 positive NSCLC and other ROS1-positive solid tumours. Jideytro is GSK's first approved medicine in lung cancer and was added to the portfolio through the acquisition of Nuvalent. In September 2026, GSK announced positive results from the registrational phase I/II ARROS-1 trial evaluating zidesamtinib in patients with advanced or metastatic ROS1-positive TKI-naïve NSCLC. The data were presented in a Presidential Symposium session at the 2026 World Conference on Lung Cancer and will support a planned supplemental New Drug Application to the US FDA this year to expand the indication to include first-line treatment. Key trials for Jideytro: Trial name (population)Phase Design Timeline Status ARROS-1 (ROS1+ non-small cell lung cancer andother solid tumours;NSCLC) I/II A study of the highly selective ROS1 inhibitorzidesamtinib (NVL-520) in patients with advancedNSCLC and other solid tumors Trial start:Q1 2022 Active neladalkib: Neladalkib is an investigational ALK tyrosine kinase inhibitor (TKI) designed to maintain activity against a broad range of ALK resistance mutations, while minimising off-target activity and optimising penetration into the central nervous system (CNS). Neladalkib was previously granted US Breakthrough Therapy designation for the treatment of patients with locally advanced or metastatic ALK-positive NSCLC who have been previously treated with 2 or more ALK TKIs and Orphan Drug designation for ALK-positive NSCLC. The phase I/II ALKOVE-1 study is ongoing in patients with advanced ALK-positive NSCLC and other solid tumours, and the phase III ALKAZAR trial is evaluating neladalkib versus alectinib in first-line ALK-positive NSCLC. Key trials for neladalkib: Trial name (population)Phase Design Timeline Status ALKOVE-1 (ALK+ non-small cell lung cancer andother solid tumours;NSCLC) I/II A study of neladalkib (NVL-655) in patients withadvanced NSCLC and other solid tumors harboringALK rearrangement or activating ALK mutation Trial start:Q2 2022 Active ALKAZAR (1L ALK+non-small cell lungcancer; NSCLC) III A phase III study of the selective anaplastic lymphomakinase (ALK) inhibitor NVL-655 compared toalectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer(NSCLC) Trial start:Q3 2025 Active HIV
Page 33
As a pioneer in long-acting injectables, ViiV Healthcare, majority owned by GSK, remains focused on advancing the next- generation of INSTI-powered HIV innovation. In Q3, topline phase IIIb CROWN data demonstrated Cabenuva’s (cabotegravir + rilpivirine; CAB + RPV LA) superior efficacy versus standard of care oral anti-retroviral therapy in people with unsuppressed HIV. These data address an important unmet need and significant growth opportunity and will be shared with health authorities for regulatory review. At IDWeek 2026, data were shared adding to the significant body of clinical and real-world evidence for long-acting injectables. Five-year OPERA data further reinforced durable effectiveness of CAB LA + RPV in the real world, while prevention data showed very low HIV acquisition with CAB LA for PrEP, consistent with registrational trials. In-vitro data for VH184 – the first potential third-generation INSTI – were also shared further highlighting an enhanced resistance profile against first- and second-generation INSTI-resistant strains. For the 3x a year long-acting injectable candidate for HIV PrEP (new intramuscular formulation of cabotegravir), data are now in house from the EXTEND 4M pharmacokinetic (PK) study. Analyses are underway to fully characterise the new formulation ahead of sharing the data package with regulators. Key HIV trials: Trial name (population)PhaseDesign Timeline Status EXTEND 4M (HIV)NCT06741397 IIb Phase IIb single arm, repeat dose study to evaluate thePK profile, safety and tolerability of a new formulationof cabotegravir LA injected intramuscularly every fourmonths in adolescent and adult participants at risk ofHIV acquisition. Trial start:Q4 2024 Active, notrecruiting, dataanalysis underway CUATRO (HIV)NCT07650916 III Phase III, randomised, multicenter, parallel-group, non-inferiority, open-label study evaluating the efficacy,safety, and tolerability of new cabotegravir andrilpivirine formulations or cabotegravir long-acting plusrilpivirine in adults and adolescents with HIV who arevirologically suppressed on ART Trial start:Q2 2026 Active, recruiting Infectious Diseases Arexvy (respiratory syncytial virus vaccine, adjuvanted) GSK continues to progress the life-cycle innovation of Arexvy, its Respiratory Syncytial Virus (RSV) vaccine for adults, with expanded indications in new populations and geographies. The vaccine is approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years of age and older in over 70 countries. It is also approved for use in adults aged 50–59 at increased risk (AIR) for LRTD caused by RSV due to certain underlying medical conditions in over 60 countries, including the US and Japan. In the US and Japan, it is approved for use in adults aged 18–49 years AIR and in the European Economic Area for adults aged 18 years and older. Arexvy is not for use in pregnant individuals. In July, the US FDA approved an update to the Arexvy prescribing information to include data in immunocompromised (IC) adults aged 18 years and older. Arexvy is approved for use in IC adults aged 18 years and older in the European Economic Area and in IC adults aged 18 years and older in Japan. China’s Center for Drug Evaluation (CDE) is reviewing a regulatory application for Arexvy for the prevention of LRTD caused by RSV in adults aged 60 years and older. A decision is expected in 2027. Key trials for Arexvy: Trial name (population)Phase Design Timeline Status RSV OA=ADJ-004(Adults aged ≥60 years) NCT04732871 III A randomised, open-label, multi-country trial to evaluatethe immunogenicity, safety, reactogenicity and persistenceof a single dose of the RSVPreF3 OA investigationalvaccine and different revaccination schedules in adultsaged 60 years and above Trial start:Q1 2021 Primarydatareported:Q2 2022 Active, notrecruiting;primaryendpoint met RSV OA=ADJ-012(Adults aged ≥60 years ) NCT06534892 IIIb An extension and crossover vaccination study on theimmune response and safety of a vaccine againstRespiratory Syncytial Virus given to adults 60 years ofage and above who participated in RSV OA=ADJ-006study Trial start:Q3 2024 Active, notrecruiting RSV OA=ADJ-031(Immunocompromised adultsaged ≥18 years) NCT07092865 IIb A non-randomised, controlled, open-label, extensionstudy to evaluate the persistence of immune response ofthe adjuvanted RSVPreF3 vaccine and the safety andimmunogenicity following revaccination in lung andkidney transplant recipients (aged 18 years and above) Trial start:Q3 2025 Active, notrecruiting RSV OA=ADJ-028 (Adults 18 to 59 years of age atincreased risk for RSV disease) NCT07220109 III A randomised, controlled, observer blind, immuno-bridging study to evaluate immunogenicity, reactogenicityand safety of a single dose of the RSVPreF3 OAinvestigational vaccine in Chinese adults 18-59 years ofage at increased risk of RSV Disease Trial start:Q4 2025 Active, notrecruiting mRNA seasonal flu (double target flu HA-NA vaccine candidate) In August 2026, GSK presented positive phase II data for its mRNA seasonal influenza (flu) vaccine candidate at the OPTIONS XIII Conference for the Control of Influenza. GSK’s vaccine candidate showed higher immune responses against all influenza strains tested compared to licensed standard dose and high dose inactivated flu vaccines in younger and older adults respectively, and was generally well tolerated. Based on these results, in September 2026, GSK started the first phase III trial of an mRNA flu vaccine designed to target both haemagglutinin (HA) and neuraminidase (NA), the primary surface antigens that cause the flu virus to bind and spread. While licensed flu vaccines primarily target HA, GSK’s vaccine candidate
Page 34
is specifically designed to also target NA. Growing evidence suggests this could help improve protection, illness severity and transmission. In July 2026, the US Food and Drug Administration (FDA) granted the vaccine candidate Fast Track designation for the targeted age indication, reflecting the urgent need to improve flu protection. Key trials: Trial name (population)Phase Design Timeline Status DUET-006(Adults ≥65 Years ofAge) III A Phase 3 randomised, Observer-Blind, ControlledStudy to Evaluate the Clinical Efficacy of an mRNABased Seasonal Influenza Vaccine in Older Adults ≥65Years of Age Trial start:September2026 Recruiting DUET-004(Adults 18-64 Years ofAge) III A Phase 3 randomised, Observer-Blind, ControlledStudy to Evaluate the Immunogenicity, Reactogenicityand Safety of an mRNA-based Seasonal InfluenzaVaccine, in adults 18-64 Years of age Trial start:October 2026 Recruiting Hibsago (HBV ASO) (bepirovirsen) Hibsago is a triple-action antisense oligonucleotide - a first in class new treatment option for people with chronic hepatitis B (CHB). It is designed to inhibit the replication of viral DNA in the body, suppress the level of hepatitis B surface antigen (HBsAg) in the blood, and stimulate the immune system to increase the chances of a durable and sustained response. In August 2026, Hibsago was approved as a functional cure for CHB in Japan – the first approval anywhere in the world. This was followed by approval by the US FDA in October 2026. These decisions were accelerated by regulatory designations reflecting Hibsago’s innovation and potential to address significant unmet need in CHB. Reviews are also underway in other markets including China, supported by Breakthrough Therapy Designation and Priority Review and the EU. Further submissions are planned for 2027. To further expand development of novel sequential regimens, GSK entered an agreement for an exclusive worldwide license to develop and commercialise daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), an investigational hepatitis B virus-targeted small interfering ribonucleic acid (siRNA) therapeutic. This agreement provides an opportunity to investigate a novel sequential regimen to pursue functional cure in an even broader patient population with bepirovirsen. Phase IIb trials for this sequential therapy started in Q4 2024. Key trials for bepirovirsen: Trial name (population)Phase Design Timeline Status B-Well 1 bepirovirsen innucleos(t)ide treatedpatients (chronic hepatitisB) NCT05630807 III A multicentre, randomised, double-blind, placebo-controlled trial to confirm the efficacy and safety oftreatment with bepirovirsen in participants withchronic hepatitis B virus Trial Start:Q1 2023 Completed; primaryendpoint met B-Well 2 bepirovirsen innucleos(t)ide treatedpatients (chronic hepatitisB) NCT05630820 III A multicentre, randomised, double-blind, placebo-controlled trial to confirm the efficacy and safety oftreatment with bepirovirsen in participants withchronic hepatitis B virus Trial Start:Q1 2023 Completed; primaryendpoint met B-United bepirovirsensequential therapy withdaplusiran/tomligisiran innucleos(t)ide treatedpatients (chronic hepatitisB) NCT06537414 IIb A multicentre, randomised, partially placebo-controlled, double-blind study to investigate thesafety and efficacy of sequential therapy withdaplusiran/tomligisiran followed by bepirovirsen inparticipants with chronic hepatitis B virus onbackground nucleos(t)ide analogue therapy Trial start:Q4 2024 Active, not recruiting B-Sure Long-term Follow-up Study to EvaluateDurability of TreatmentResponse in PreviousBepirovirsen StudyParticipantsNCT04954859 II A global multicenter, long-term follow-up study toassess durability of efficacy, as measured bymaintenance of treatment response from the parentstudy, in participants who participated in a previousbepirovirsen study and achieved a complete orpartial response. Eligible participants will beenrolled in this study after completing the end ofstudy (EoS) visit in one of five parent bepirovirsenstudies. Trial Start:Q1 2021 Active, not recruiting Reporting definitions CAGR (Compound annual growth rate) CAGR is defined as the compound annual growth rate and shows the annualised average rate for growth in sales and core operating profit between 2021 to 2026, assuming growth takes place at an exponentially compounded rate during those years. CER and AER growth In order to provide investors with a measure of year-on-year growth excluding the impact of exchange rate movements, it is the Group’s practice to discuss its results in terms of constant exchange rate (CER) growth. This represents growth calculated as if the exchange rates used to determine the results of overseas companies in Sterling had remained unchanged from those used in the comparative period. CER% represents growth at constant exchange rates. For those countries which qualify as hyperinflationary as defined by the criteria set out in IAS 29 ‘Financial Reporting in Hyperinflationary Economies’ (Argentina and Turkey) CER growth is adjusted
Page 35
using a more appropriate exchange rate where the impact is significant, reflecting depreciation of their respective currencies in order to provide comparability and not to distort CER growth rates. AER% represents growth at actual exchange rates. Core Earnings per share Unless otherwise stated, Core earnings per share refers to Core basic earnings per share. Core Operating Margin Core Operating margin is Core operating profit divided by turnover. Core operating profit is a key financial measure used by management to evaluate performance. Free cash flow Free cash flow is defined as the net cash inflow/outflow from operating activities less capital expenditure on property, plant and equipment and intangible assets, contingent consideration payments, net finance costs, and distributions to non-controlling interests, contributions from non-controlling interests plus proceeds from the sale of property, plant and equipment and intangible assets, and dividends received from joint ventures and associates. Free cash flow provides investors with a measure of cash flows that are available to pay shareholder distributions and to fund strategic acquisitions. It is used by management for planning and reporting purposes and in discussions with and presentations to investment analysts and rating agencies. Free cash flow growth is calculated on a reported basis. A reconciliation of net cash inflow from operations to free cash flow from operations is set out on page 34. Free cash flow conversion Free cash flow conversion is free cash flow from operations as a percentage of profit attributable to shareholders. Free cash flow conversion provides investors with a measure of turning profit into cash. General Medicines General Medicines are usually prescribed in the primary care or community settings by general healthcare practitioners. For GSK, this includes medicines for inhaled respiratory, dermatology, antibiotics and other diseases. Non-controlling interest (NCI) Non-controlling interest is the equity in a subsidiary not attributable, directly or indirectly, to a parent. Percentage points Percentage points of growth which is abbreviated to ppts. RAR (Returns and Rebates) GSK sells to customers both commercial and government mandated contracts with reimbursement arrangements that include rebates, chargebacks and a right of return for certain pharmaceutical products principally in the US. Revenue recognition reflects gross-to-net sales adjustments as a result. These adjustments are known as the RAR accruals and are a source of significant estimation uncertainty and fluctuation which can have a material impact on reported revenue from one accounting period to the next. Risk adjusted sales Pipeline risk-adjusted sales are based on the latest internal estimate of the probability of technical and regulatory success for each asset in development. Specialty Medicines Specialty Medicines are typically prescription medicines used to treat complex or rare chronic conditions. For GSK, this comprises medicines for infectious diseases, HIV, Respiratory, Immunology & Inflammation, and Oncology. Total Net debt Net debt is defined as total borrowings less cash, cash equivalents, liquid investments, and short-term loans to third parties that are subject to an insignificant risk of change in value. The measure is used by management as it is considered a good indicator of GSK's ability to meet its financial commitments and the strength of its balance sheet (including those classified as assets held for sale and liabilities relating to assets held for sale). Total and Core results Total reported results represent the Group’s overall performance. GSK uses a number of non-IFRS measures to report the performance of its business. Core results and other non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. Core results are defined on page 14 and other non-IFRS measures are defined in pages 43 and 44. Total Operating Margin Total Operating margin is Total operating profit divided by turnover. Total Earnings per share Unless otherwise stated, Total earnings per share refers to Total basic earnings per share. Working capital Working capital represents inventory and trade receivables less trade payables. Year to date
Page 36
Year to date is the nine-month period in the year to 30 September 2026 or the same prior period in 2025 as appropriate. Guidance and Outlooks, assumptions and cautionary statements 2026 Guidance GSK reaffirms its full-year 2026 guidance at constant exchange rates (CER). GSK expects its turnover to increase between 3% to 5%, at the upper half of the range, and Core operating profit to increase between 7% to 9%, at the upper half of the range. Core earnings per share is expected to increase between 7% to 9%, at the lower half of the range. The Group has made planning assumptions that we expect turnover for Specialty Medicines to increase by a low double-digit percentage, Vaccines to be broadly stable to an increase at a low-single digit percentage, and General Medicines to decline by a mid-single digit to low single-digit percentage. 2021-2026 and 2031 Outlooks In February 2025, GSK set out improved outlooks for 2031 which are detailed in the 2024 full year and fourth quarter results on gsk.com (1) . Assumptions and basis of preparation related to 2026 Guidance, 2021-26 and 2031 Outlooks In outlining the guidance for 2026, and outlooks for the period 2021-26 and for 2031, the Group has made certain assumptions about the macro-economic environment, the healthcare sector (including regarding existing and possible additional governmental legislative and regulatory reform), the different markets and competitive landscape in which the Group operates and the delivery of revenues and financial benefits from its current portfolio, its development pipeline and restructuring programmes, including the Accelerate Growth programme as outlined on page 17. As previously announced, on 19 December 2025, GSK entered into an agreement with the US Administration to lower the cost of prescription medicines for American patients and exclude both GSK and ViiV Healthcare from Section 232 tariffs for three years. On 9 April 2026, GSK, ViiV Healthcare, and the US Government entered into a definitive agreement reflecting Section 232 tariff relief through 20 January 2029 (subject to implementation and ongoing compliance). As part of that implementation, GSK and ViiV Healthcare each signed a GENEROUS Model Manufacturer Participation Agreement with the Centers for Medicare and Medicaid Services effective 15 June 2026. With these agreements GSK and ViiV Healthcare have committed certain products to participate in the voluntary GENEROUS Model. GSK and ViiV have also entered into GENEROUS Model Supplemental Rebate Agreements with several interested states and will work with the other states going forward to execute Supplemental Rebate Agreements as requested. Our full year guidance is inclusive of the expected impact of these agreements. 2026 Guidance These planning assumptions as well as operating profit, earnings per share guidance and dividend expectations assume no material interruptions to supply of the Group’s products, no material mergers, acquisitions or disposals, no material litigation or investigation costs for the Company (save for those that are already recognised or for which provisions have been made) and no change in the Group’s shareholdings in ViiV Healthcare. The assumptions also assume no material changes in the healthcare environment or unexpected significant changes in pricing or trade policies, including tariffs (except as noted above), as a result of government or competitor action. The 2026 guidance factors in all divestments and product exits announced to date. 2021-26 and 2031 Outlooks The assumptions for GSK’s revenue, Core operating profit, Core operating margin and cash flow outlooks, 2031 revenue outlook and margin expectations through dolutegravir loss of exclusivity assume the delivery of revenues and financial benefits from its current and development pipeline portfolio of medicines and vaccines (which have been assessed for this purpose on a risk-adjusted basis, as described further below); regulatory approvals of the pipeline portfolio of medicines and vaccines that underlie these expectations (which have also been assessed for this purpose on a risk-adjusted basis, as described further below); no material interruptions to supply of the Group’s products; successful delivery of the ongoing and planned integration and restructuring plans, including the Accelerate Growth programme as outlined on page 17; no material mergers, acquisitions or disposals or other material business development transactions; no material litigation or investigation costs for the Company (save for those that are already recognised or for which provisions have been made); and no change in the Group's shareholdings in ViiV Healthcare. GSK assumes no premature loss of exclusivity for key products over the period. The assumptions for GSK’s revenue, Core operating profit, Core operating margin and cash flow outlooks, 2031 revenue outlook and margin expectations through dolutegravir loss of exclusivity also factor in all divestments and product exits announced to date as well as material costs for investment in new product launches and R&D. Risk-adjusted sales includes sales for potential planned launches which are risk-adjusted based on the latest internal estimate of the probability of technical and regulatory success for each asset in development. Notwithstanding our guidance, outlooks and expectations, there is still uncertainty as to whether our assumptions, guidance, outlooks and expectations will be achieved. All outlook statements are given on a constant currency basis and use 2025 average exchange rates as a base (£1/$1.31, £1/€1.17, £1/Yen 198). (1) https://www.gsk.com/media/slrhnzie/fy-2024-results-announcement.pdf Assumptions and cautionary statement regarding forward-looking statements
Page 37
The Group’s management believes that the assumptions outlined above are reasonable, and that the guidance, outlooks, and expectations described in this report are achievable based on those assumptions. However, given the forward-looking nature of these guidance, outlooks, and expectations, they are subject to greater uncertainty, including potential material impacts if the above assumptions are not realised, and other material impacts related to foreign exchange fluctuations, macro-economic activity, the impact of outbreaks, epidemics or pandemics, changes in legislation, regulation, government actions and policies, including the impact of any potential tariffs or other restrictive trade policies on the Group's products, or intellectual property protection, product development and approvals, actions by our competitors, and other risks inherent to the industries in which we operate. This document contains statements that are, or may be deemed to be, “forward-looking statements”. Forward- looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'aim', 'ambition', 'anticipate', 'believe', 'could', 'estimate', 'expect', 'goal', 'intend', 'may', 'outlook', 'plan', 'project', 'seek', 'should', 'target', 'will' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulation, the UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The reader should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the SEC. All readers, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and readers are cautioned not to place undue reliance on the forward-looking statements. All guidance, outlooks and expectations should be read together with the guidance and outlooks, assumptions and cautionary statements in this Q3 2026 earnings release and in the Group's 2025 Annual Report on Form 20-F. Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate. The Group cautions investors that a number of important factors, including those in this document, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under ‘Risk Factors’ in the Group’s Annual Report on Form 20-F for 2025 and as described on pages 48 and 49 of the Q2 2026 earnings release. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this report. Independent review report to GSK plc Conclusion We have been engaged by GSK plc (“the company”) to review the condensed financial information in the Results Announcement of the company for the three and nine months ended 30 September 2026. The condensed financial information comprises: • the income statement and statement of comprehensive income for the three and nine month periods ended 30 September 2026 on page 20 and 21; • the balance sheet as at 30 September 2026 on page 22; • the statement of changes in equity for the nine-month period then ended on page 23; • the cash flow statement for the nine-month period then ended on page 24; and • the accounting policies and basis of preparation and the explanatory notes to the condensed financial information on pages 25 to 34 that have been prepared applying consistent accounting policies to those applied by GSK plc and its subsidiaries (“the Group”) in the Annual Report 2025, which was prepared in accordance with UK-adopted international accounting standards in conformity with the requirements of the Companies Act 2006 and the IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB). Based on our review, nothing has come to our attention that causes us to believe that the condensed financial information in the Results Announcement for the three and nine months ended 30 September 2026 is not prepared, in all material respects, in accordance with the accounting policies set out in the accounting policies and basis of preparation section on page 31. Basis for Conclusion We conducted our review in accordance with International Standard on Review Engagements (UK) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Financial Reporting Council for use in the United Kingdom (ISRE (UK) 2410). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. As disclosed on page 31, the annual financial statements of the Group are prepared in accordance with United Kingdom adopted international accounting standards. The condensed set of financial information included in this Results Announcement have been prepared in accordance with the accounting policies set out in the accounting policies and basis of preparation section on page 31.
Page 38
Conclusion Relating to Going Concern Based on our review procedures, which are less extensive than those performed in an audit as described in the Basis for Conclusion section of this report, nothing has come to our attention to suggest that the directors have inappropriately adopted the going concern basis of accounting or that the directors have identified material uncertainties relating to going concern that are not appropriately disclosed. This Conclusion is based on the review procedures performed in accordance with ISRE (UK) 2410; however future events or conditions may cause the entity to cease to continue as a going concern. Responsibilities of the directors The directors are responsible for preparing the Results Announcement of the company in accordance with the Disclosure Guidance and Transparency Rules of the United Kingdom’s Financial Conduct Authority. In preparing the Results Announcement, the directors are responsible for assessing the company’s ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so. Auditor’s Responsibilities for the review of the financial information In reviewing the Results Announcement, we are responsible for expressing to the company a conclusion on the condensed financial information in the Results Announcement. Our Conclusion, including our Conclusion Relating to Going Concern, are based on procedures that are less extensive than audit procedures, as described in the Basis for Conclusion paragraph of this report. Use of our report This report is made solely to the company in accordance with ISRE (UK) 2410. Our work has been undertaken so that we might state to the company those matters we are required to state to it in an independent review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company, for our review work, for this report, or for the conclusions we have formed. Deloitte LLP Statutory Auditor London, United Kingdom 28 October 2026 Glossary Terms used in the Announcement Brief description 1L First line 2L Second line ADC Antibody-drug conjugate ADP Adenosine diphosphate ALK Anaplastic lymphoma kinase ASO Antisense oligonucleotide CCL Contingent consideration liability CDC Centers for Disease Control and Prevention CDE Center for Drug Evaluation COPD Chronic obstructive pulmonary disease CRSwNP Chronic rhinosinusitis with nasal polyps cUTI Complicated urinary tract infection dMMR Deficient mismatch repair DRIP Dividend reinvestment plan DTG Dolutegravir EGPA Eosinophilic granulomatosis with polyangiitis EMA European Medicines Agency ESOP Employee share ownership plan GENEROUS GENErating cost Reductions fOr U.S. Medicaid GIST Gastrointestinal stromal tumour HBV Hepatitis B virus HES Hypereosinophilic syndrome IBS Irritable bowel syndrome INSTI Integrase strand transfer inhibitors IRA Inflation Reduction Act IV Intravenous LAI Long acting injectables (includes Apretude and Cabenuva) LoE Loss of exclusivity LRTD Lower respiratory tract disease MAPS Multi antigen presenting system MASH Metabolic dysfunction-associated steatohepatitis MMRV Measles, mumps, rubella and varicella Mo-Rez Mocertatug rezetecan mRNA Messenger ribonucleic acid MSI-H Microsatellite instability high
Page 39
NDA New Drug Application OA Older adults Oral 2DR Oral 2 drug regimen (includes Dovato and Juluca) PARP Poly ADP ribose polymerase PD-1 Programmed death receptor-1 blocking antibody PDUFA Prescription Drug User Fee Act PK Pharmacokinetics ppts Percentage points PrEP Pre-exposure prophylaxis PRIME Priority Medicines RCC Refractory chronic cough RI&I Respiratory, Immunology & Inflammation Ris-Rez Risvutatug rezetecan RNS Regulatory news service RSV Respiratory syncytial virus SC Subcutaneous SCLC Small cell lung cancer SG&A Selling, general and administrative expenses, net of other sundry income siRNA Small interfering RNA SITT Single inhaler triple therapy TKI Tyrosine kinase inhibitor TSLP Thymic stromal lymphopoietin ULA Ultra long acting uUTI Uncomplicated urinary tract infection Product List Trademark Generic Product Area Indication(s) Anoro Ellipta umeclidinium bromide/vilanterol trifenatateGeneralmedicines COPD Apretude cabotegravir Specialtymedicines HIV prevention Arexvy respiratory syncytial virus vaccine Vaccines Respiratory syncytial virus vaccination Benlysta(SC and IV) belimumab Specialtymedicines Systemic lupus erythematosus, lupusnephritis Bexsero meningococcal group-B vaccine Vaccines Meningitis group B prophylaxis Blenrep belantamab mafodotin Specialtymedicines Relapsed/refractory multiple myeloma Blujepa gepotidacin Generalmedicines Uncomplicated UTI, UncomplicatedGonorrhoea Boostrix diphtheria, tetanus, acellular pertussisVaccines Diphtheria, tetanus, acellularPertussis booster vaccination Cabenuva/Vocabria +Rekambys cabotegravir, rilpivirine Specialtymedicines HIV/AIDS Cervarix HPV 16 & 18 virus like particles (VLPs), AS04adjuvant (MPL + aluminium hydroxide) Vaccines Human papilloma virus type 16 and 18 Dovato dolutegravir/lamivudine Specialtymedicines HIV/AIDS Exdensur depemokimab Specialtymedicines Severe Asthma, CRSwNP Flixotide / Flovent fluticasone propionate Generalmedicines Asthma Fluarix / FluLaval split inactivated influenza antigens (2 virussubtypes A and 2 subtype B) Vaccines Seasonal influenza prophylaxis Hibsago bepirovirsen Specialtymedicines chronic hepatitis B (CHB) Infanrix/Pediarix diphtheria, tetanus, pertussis, polio, hepatitis B,haemophilus influenzae type B (EU) Vaccines Prophylaxis against diphtheria, tetanus,pertussis, polio, hepatitis B, Haemophilusinfluenzae type B (EU) Jemperli dostarlimab Specialtymedicines dMMR/MSI-H recurrent/ advancedendometrial cancer, dMMR solid tumours Jideytro zidesamtinib Specialtymedicines ROS1-positive non-small cell lung cancer(NSCLC), Juluca dolutegravir/rilpivirine Specialtymedicines HIV/AIDS Menveo meningococcal group A, C, W-135 and Y conjugatevaccine Vaccines Meningitis group A, C, W-135 and Yprophylaxis Nucala mepolizumab Specialtymedicines Asthma, COPD, CRSwNP, EGPA, HES Ojjaara/Omjjara momelotinib Specialtymedicines Myelofibrosis in patients with anaemia Penmenvy meningococcal groups A, B, C, W, and Y vaccine Vaccines Meningitis group A, B, C, W-135 and Yprophylaxis Priorix, Priorix Tetra,Varilrix live attenuated MMR, varicella and MMRVvaccines Vaccines Measles, mumps, rubella and chickenpoxprophylaxis Relvar/Breo Ellipta fluticasone furoate/vilanterol trifenatateGeneralmedicines Asthma, COPD Rotarix human rotavirus RIX4414 strain Vaccines Rotavirus prophylaxis
Page 40
Rukobia fostemsavir Specialtymedicines HIV/AIDS Seretide / Advair salmeterol xinafoate, fluticasone propionateGeneralmedicines Asthma, COPD Shingrix zoster vaccine recombinant, adjuvantedVaccines Herpes zoster (shingles) Synflorix conjugated pneumococcal polysaccharideVaccines Prophylaxis against invasive disease,pneumonia, acute otitis media Tivicay dolutegravir Specialtymedicines HIV/AIDS Trelegy Ellipta fluticasone furoate/vilanteroltrifenatate/umeclidinium bromide Generalmedicines COPD, asthma Triumeq dolutegravir, lamivudine and abacavir Specialtymedicines HIV/AIDS Ventolin salbutamol sulphate Generalmedicines Asthma, COPD Zejula niraparib Specialtymedicines Ovarian cancer Brand names appearing in italics throughout this document are trademarks of GSK or associated companies or used under licence by the Group.
Page 41
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial ConductAuthority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution ofthis information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the informationcontained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services.For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our PrivacyPolicy. END